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ABSTRACT
4 (I H)-Quinolone is an important phamlacophore found in a variety of biologically active
molecules including clinically used antimalarial, antibacterial, anti-intlammatory,
anticancer and antiviral agents. The diverse biological protiles of qui no lone derivatives
have attracted researchers interested in exploring novel quinolone-basedcompoundsthat
may overcome the unwanted effects of life-saving drugs while presenting new
mechanisms of action and high efficacy.
Among the quinolone derivatives, 4 (1H)-quinolone-3carboxylic acid derivatives have
c1isplayedan excellent antibacterial protile. This includes high efficacy, broad spectrum
of activity, high tolerability, and effectiveness against bacterial strains resistant to
available antibiotics. The work presented in this thesis was pertolmed in order to discover
novel polycyclic quinolones with potential antibacterial activity, focussing on activity
against resistant bacterial strains. This work involves the c1esign and synthesis of various
fusedquinolonesandtheirillvilrGmicrobiologicalactivity.lnordertounclerstandthe
mechanism behind the loss of activity, ill.l'ilico moleculardocking was carried out on the
DNAgyraseenzyme.
The results obtained in this study showed that the synthesized quinolonederivatives have
good binding affinities to DNA gyrase. However, these derivatives were not able to form
stable bonds with the enzyme, which may account for the lack of bioactivity exhibited by
these derivatives.
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CHAPTER 1
Quinolones: An Overview
Clrllpterl-QuiIlOIOlH'S:AIIO\lt!rview
1.1 Introduction
A phannacophore is a part of a molecule which is responsible for interaction with
receptors, biomolecules etc. IUPAC defines a pharmacophore as "An ensemble of steric
and electronic feature that is necessary to ensure the optimal supramolecularinteractions
with a specific biological target and to trigger its biological response" [Ia]. It is well
known that certain types of phannacophores have intluence on improving the drug ability
profile of some molecules as compared to others. These specific typesofpharmacophores
are associated with improvement in the bioavailability of drugs and, as a result,
modifying their pharmacokinetic profiles. The concept of "privileged structures" was
first proposed by Evans [Ib]. Privileged structure refers to a molecular scaffold whose
structure contains two or three ring systems, arranged in such a manner so as to allow a
very high degree of versatility in binding with the receptors [2]. In this context, a
quinolone scaffold can beconsideredasa tlUly privileged structure.
The very first quinolone was discovered by serendipity. It was discovered by
Lesher et al. (1962) as an impurity while manufacturing chloroquine, an antimalarial
agent[3].Sincethattime,numerousderivativesofquinoloneshavebeendiscovered,and
many of them are in clinical use. Based on their main clinical use and decade of
discovery, they can be placed in four different groups (A, B, C,D) as depicted in Figure
I-I.
Quinolones as antibacterial agents have been known for a very long time.
However, they are still a hot topic for current research. This is mainly because of
continuous development of bacterial resistance against currentlyused antibiotics. This has
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guided the current trend of antibiotics research to tocus mainly on development of novel
quinolone antibacterials which will be active against highly resistant strains [1-4].
()I·II':()I.O\it:~
Figure I-I: Development of quinolones
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1.2 Chemistry of Quinolones
Substitutionofa single carbon atom ona benzene ring with nitrogen gives rise to
the pyridine skeleton, while the same substitution on a napthalene nucleus results in a
quinoline or isoquinoline nucleus (Figure 1-2). Quinoline is a liquid with a high boiling
point, first extracted in 1834 from coal tar. lsoquinoline is a solid with a low melting
point, first extracted in 1885 from the same source [14].
o o
Figure 1-2: Stmctures of pyridine and quinoline nuclei.
The Schematic numbering ofa quinoline nucleus is shown in Figure 1-3.
6C05"'~3
7 : ~h2
Figure 1-3: Schematic numbering of quinoline nucleus.
A quinolone is the keto tautomer form of a quino line substituted with a hydroxyl
functional group. Quinolones exist in isomeric formsof4-and 2-quinolones as depicted
in Figures 1-4 and 1-5.
Figure 1-4: Tautomeric IOlmsof2-quinolone
Figure 1-5: Tautomeric formsof4-quinolone
Chapterl-Qu;"o{m,es:Alloverv;ew
Among the various known methods for the synthesis of quinolones, a few
important procedures are described below.
1.2.1 Gould Jacob's QuinoloncSynthcsis
This is one of the oldest and established methods for the syntheses of
quinolones. Preparation of quinolones by this method relies on an additio/l-
elimi/latio/l reaction between various substituted ani lines and dialkyl
alkoxymethylenemalonate as shown in Schcme 1-1 [5]. The product fOllned by
the addition-elimination reaction between substituted aniline and dialkyl
alkoxymethylenemalonate undergoes thermal cyclization at high temperature to
give quinoline-4(1H)-one system. N-Alkylation of this scaffold, followed by
hydrolysis of the ester group, affordsN-substituted 4 (1H)-quinolone-3-carboxylic
acid.
Schcmc I-I: Gould-Jacobs reaction.
Chaplcr !-Qllill(}!OIlCS:.·tll0W!,.""cw
1.2.2 Dieckmann Cyciization of Diesters
This is a suitable procedure for the synthesis ofaza- and diazaquinolone
carboxylic acids that was reported by Pesson et {II. [6]. This process is based on
basecatalyzedintramolecularcyclizationofdiestersasdepictedinScheme 1-2.
The first step involves the regioselective reaction between ethyl ester of 2,6-
dichloro-5-fluoronicotonicacid (l)withN-acetylpiperazinetofol1116-piperazinyl
derivative 2. The treatment of compound 2 with the ethyl ester of 3-
ethylaminopropionic acid leads to the formation of diester 3, which in turn
undergoes intramolecular ring closure with potassium tert-butoxide to form ethyl
ester oftetrahydronaphthyridine carboxylic acid 4. The dehydrogenation 01'4 by
the means of chIoranil yields the ethyl esterofnaphthyridone carboxylic acid 5
which then gets hydrolysed to the tluoroquinolone(enoxacin).
FXX
COOE
\, FXX
COOE
' FXXCOOE' CI --- I _h__ I "" --
CI N""CI rN N"CI r N hN~COOE'
1 AC/N~ 2 AC/N~ 3 ~,
F~COOE'J F~COOE'. F~COOH~.) ~)_C__ ~.)
.0 : I, .0: 1. .0 h I,
Ac Ac Ac enoxacin
ja) N-JCl.:lylpipcmzinl.:, CI11CN; b) EINli(CII~)~CO~Et, DMF, NaIIC01. 120 "r: c) KO('(C1 Ilh. IOluclll:; d) chlorl.mil; l:l
Scheme 1-2: Synthesis of enoxacin by Dieckmann Cyclization method
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1.2.3 Camps quinoline synthesis
In Camps quinoline synthesis, alkaline cyclization of an N-acylated-o-
aminobenzophenone affords the corresponding 2- or 4-hydroxyquinolines as
shown in Scheme 1-3[7-13].
~RLJlrceCOCH301r ~~.~( -- I ---- ~.A
,0 ~OH 'o~O ,0 ~ CH,R
Scheme 1-3: Camps quinoline synthesis
1.2.4 Conrad-Limpach 4-quinolone synthesis
This is another name reaction that is employed for the synthesis of4-
quinolones. It involves the reaction between aniline and 3-oxoblltanoate at a
temperature below 100°C. The second step in this reaction involvescyclization in
an inert solvent ata temperature around 250°C to yield 4-qllinolone derivativeas
shown in Scheme 1-4.
Scheme 1-4: Conrad-Limpach 4-quinolone synthesis
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One important modification of this reaction is the use ofa temperature above
100°C in the first step that results in the fomlationofa3-oxobutanoic acid amide,
which upon further cyclization affords the corresponding 2-quinolone derivalive
[15].
1.2.5 Synthesis of quinolones by cycloaracylation reaction
The cycloaracylation procedure was developed by Grohe el al. [16] in
1987. This procedure is depicted in Scheme 1-5. In this procedure, 2,4-Dichloro-
5-11uorobenzoyl chloride (6) reacts with ethyI3-cyclopropylaminoacrylate(7) in
the presence of triethylamine to yield the acylated product 8. Cyclization of8
under the catalytic influence of potassium carbonate produces theethylesterof
quinolone carboxylic acid 9, which is subsequently hydrolysed to its carboxylic
acid derivative 10. The reaction of 10 with piperazine leads to the generation of
quinoloneantimicrobial (in this case, ciprofloxacin) [17]
FWOCOOH F~COOH
I"" I -"--- ~)
CI -&N rN-&N
10 L HN~ L
Scheme 1-5: Synthesisofciprofloxacin bycycloaracylation reaction
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1.2.6 Meth-CohnQuinoloneSynthesis
This approach of quino10ne synthesis was developed by Meth-Cohn in
1986 (18]. In this reaction a Vilsmeier complex consisting of N-
methylfomlanilide (II) and phosphoryl chloride is reacted with methylmalonyl
chloride (12) to produce its quinolinium salt 13. Treatment of this quinolinium salt
with ammonium hexafluorophosphate affords 4-chloro-3-methoxycarbonyl-l-
methylquinolinium hexafluorophosphate (14). Compound 13 is converted to 1-
methyl-4-quinolone-3-carboxylicacid 15 by treatment with excess alkali followed
by acidification as depicted in Scheme 1-6.
l'Oel,
Meex:x:-CH2COCl --- ClOCJC~HJ ro1h bH: /1:~~ C:HJ
CHJ
ce~C~HJ
bHJ PF6H
Scheme 1-6: Meth-Cohnquinolonesynthesis
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1.2.7 Biere and Seelen Approach for quinolone synthesis
This method for quinolone synthesis was developed by Biere and Seelen in
1976 as shown in Scheme 1-7 [19]. This procedure involves the Michael addition
ofmethylanthranilate(16)todimethylacetylenedicarboxylate(17) to give rise to
the enamino esters 18. This enamino ester then undergoes cyclization to the
quinolonedicarboxylic acid ester 19 in the presence of strong base such as sodium
hydride or potassium lerl-butoxide. The ester-acid 20 or the dicarboxylic acid 21
are obtained after regioselective or complete alkaline hydrolysis of 19. The
quinolonecarboxylic acid ester 22 is then obtained by thermal decarboxylation
reaction from compound 20. This method of qui no lone synthesis has never been
used {or the synthesis offluoroquinolones, mainly because of expensive starting
material and requirement of very a high temperature {or the decarboxylation
reaction to take place.
I
(')COOM! ~COOM!
(YCOOM!+ II - TNH~COOM!-Q,,~
~ COOM! NCOOM!
NH2 18 H
~~M! 19
~COOM!~COOH ~COOM!
lA,,~ + lA,,~ -- lA)~ COOH ~ COOH .0 ~
Scheme 1-7: Biereand Seelen approach for quinolone synthesis
10
Chapter 1- Qllill%lle,'1: All ol'en'iew
1.3 DNA Super coiling, replication and topoisomerase
Deoxyribonucleic acid (DNA) is a linear, double helical stmcture that carries
genetic information from one generation to another, allows mutation and recombination
and serves as a template for semi conservative replication [20]. The way and orientation
in which DNA is present in the cell is associated with certain problems.
I) DNA is present in a super condensed state inside the nucleus of cell. For example
in £. coli bacterium, the DNA is approximately 1000 fun long [21], as compared
to the cell which is 1-2 fun. To accommodate such a long strand of DNA in a
relatively small cell, it must be highly condensed. However despite super
condensation, DNA must be able to replicate, and allow transcription of individual
genes as required without becoming lethally entangled.
2) DNA has a double- helical structure. With each turn of a helix, two single strands
are wrapped around each other. Also, on an average two turns of DNA are
separated by lOA base pairs. An £. coli chromosome has 4 million base pairs.
This would mean that essentially the £. coli chromosome is intertwined about
400,000 times. In order for DNA to undergo semi conservative replication, it must
unwind by the same number of times.
3) In reality, prokaryotic DNA undergoes less than one turn for every lOA base pairs
[22]. This results in negative super coiling of DNA. Negative super coiling is an
inherent feature of prokaryotic DNA to facilitate DNA replication and
transcription. However it is an energy consuming process. Hence in order for
bacterium to generate and maintain its DNA in a negative super coil state, it must
useatremendousamountofenergy.
CIIlIpterl-Quill%lles:AllfH'en1ieJV
4) A fourth problem arises when the DNA undergoes replication or transcription.
Replication or transcription of DNA requires its helical structure to be unwrapped
into two parallel strands. This unwrapping is done by RNA polymerase. However
this causes generation of positive super coils ahead of the repl icationfork[23-26].
With continuous generation of positive super coils, eventually it becomes difficult
and a highly energy consuming process for RNA polymerase to unwind the DNA
alld carry out replication and transcription. This generation of positive super coils,
if not resolved, will lead to inefficiency of the transcription and replication
processes.
Each of these problems is resolved by a class of enzymes known as
Topoisomerases [22, 27-29]. These are the group of enzymes that alter the number
of times one single strand of a DNA duplex winds around its complementary
strand. Hence, these enzymes are very essential for cell growth and replication.
Three subtypes of topoisomerase enzyme have been discovered so far. They are:
I)Type ITopoisomerase-representedbytopoisomerase I and III inprokaryotes.
2) Type Il Topoisomerase - represented by DNA gyrase (bacterial topoisomerase
Il and mammalian topoisomerase Il) and Bacterial topoisomerase IV.
3) Special Topoisomerase-representedbythosecatalyzingtraIlsposition.
1.3.1 Bacterial TopoisomeraseI
Topoisomerase I was first isolated by James Wang [30] in 1969 from £.
coli. Type I topoisomerase is a II O-kDa protein and it is encoded by the lopA gene
[31]. This tapA gene is located at 28 min on the bacterial chromosome of E coli.
12
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Type [ topoisomerase breaks only one strand of DNA and passes it through the
other. Wang e/al. [30] observed that topoisomerase I from both bacterial and
eukaryotic sources, were able to remove negative super coils from DNA in the
absence of ATP. However eukaryotic topoisomerase I was also able to remove
positive super coil. In a prokaryotic cell, DNA gyrase along with topoisomerase I
are responsible for regulation of negative super coiling of DNA [32, 33] and hence
the enzyme is required for transcription to take place [34]. Prusselal. conducted a
study [35] on /opA mutants of E coli. These mutants were not able to produce a
functional topoisomerase enzyme. As a result it was observed that, there was
excessive accumulation of negative super coils in Plasmid pBR322 DNA of /opA
mutant bacteria. This excessive accumulation of negative super coils was
dependant on transcriptionof/elgene. Hence, this study gave direct evidence that
IOpoisomerase [is required for removal of negative super coil behind the
progressive replica/ioll fork. Quinolones can inhibit the DNA relaxation activity
of topoisomerase I at very high concentrations only [36-37].
1.3.2 Bacterial topoisomerase II (DNA Gyrase)
D A gyrase was first isolated by Martin Gellert and associates in 1976
from £. Coli bacterium [22, 27, 28, 29, 38]. Based on studies conducted with the
help of High Resolution Microscopy, it was found that the gyrase enzyme has a
heart shaped structure [39]. DNA gyrase is made up of four different subunits and
is comprised of two A subunits (GyrA) and t\vo B subunits (GyrB) [40,41]. The
GyrA subunit is encoded by the gyrA gene and GyrB subunit is encoded by gyrB
13
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gene. By using the method of small-angle neutron scattering, the mass of the
holoenzyme was found to be 353 kDa [41].
Both GyrA and GyrB subunits are responsible for different functions.
GyrA is mainly required for DNA cleavage and re-ligation with the tyrosine
residue at position 122 (Tyr-122), hence creating a temporary phosphotyrosine
bond with the broken strand of DNA. GyrB subunit, on the other hand, is mainly
responsible for the ATPase activity of the enzyme. Various studies have been
conducted using the fragments of GyrA and GyrB subunit with the aim of
identifying the functional domain of these subunits. Reece el a/. [42] found that
the addition ofa C-temlinaI33-kDa GyrA fragment improved the efficiency of the
enzyme and was able to stabilize the complex. A 47-kDa C terminal fragment of
GyrB when complexed with the GyrA subunit, was able to cause DNA relaxation
but not ATP hydrolysis. Further work was subsequently carried out to identify the
ATP binding site on the gyrase enzyme. The N-terminal region (amino acid 2
through 220) of the GyrB subunit is now known to contain the ATP binding
region [43]. This finding is based on the study of the x-ray crystallographic
structure of the gyrase enzyme. The structure of the gyrase enzyme complexing
with the DNA has been studied extensively [39, 44]. It was found in those studies
that a single turn of DNA is wrapped around the enzyme. ATP, when bound to the
GyrB subunit, was able to induce structural change to the enzyme which
eventually results in increased super coiling [44]. In other words, hydrolysable
ATP is required by the gyrase to function [45]. DNA gyrase also requires a
14
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divalent cation (mainly magnesium) to function. Replacement of magnesium with
calcium has been shown to result in an abortive DNA breakage reaction [42].
1.3.3 Bacterial TopoisomeraseIII
Srivenugopal et al. discovered topoisomerase III in 1984 [46]. This
enzyme was able to remove the negative super coil from DNA without any energy
requirement. However it needed energy in the foml of ATP to remove positive
super coils [46]. However its activity is less efficient as compared to other types
of topoisomerase [47]. Topoisomerase III can bind to both DNA as well as RNA
[49]. It is encoded by the topBgene located at 38.7 minon the£. coli genetic map
[48]. Studies were conducted on mutants where genetic information was removed
li'om 38.4 min to 39 min. Survival of these mutant bacterium have shown that
topoisomerase III enzyme is not an essential enzyme [48].
1.4 DNA Gyrase: primary target for quinolone action
In 1977, GyrA subunit was reported as a primary target of Nalidixic and
Oxolinic acid by Gellert [50] and Cozzarelli [51]. Experiments were conducted
by these investigators on purified gyrase enzyme in which GyrA subunit was
isolated from nalidixic acid resistant mutants and GyrB subunit was derived fi'OI11
the wild type population, This modified enzyme was active in the presence of
normal concentrations of nalidixic acid that inhibited the wild type enzymes,
Similar studies conducted on B. suh/ilis [52], £u/erococcus jaecalis [53], s.
15
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allrells [54], Pselldol/lollas aerllgillosa [55-58], f-1aemopllillls illjlllell::ae [59] have
shown that the GyrA subunit is also a target of quinolone action.
Two different mutations that are responsible for nalidixic acid resistance have also
been identified on the gyrS gene [60-62]. One of these mutations, nalD, was
responsible for increased resistance to newer quinolones. The other mutation,
nalC, surprisingly, produced increased susceptibility to quinolones containing
piperazine at the 7th position [63]. It was concluded in these studies that both
GyrA and GyrB subunits are targets for quinolone action.
Quinolones exert their inhibitory effect by binding to the Gyrase-DNA or
Topoisomerase IV- DNA complex. Upon binding with the complex, quinolones
induce a conformational change in the enzyme. As a result of this confomlational
change, gyrasecannow break the strands ofD A but loses its ability to re-ligate
it (Figure 1-6). The overall result is the fonnation of a quinolone-enzyme-D 1\
complex. This complex fonnation reversibly inhibits DNA and cell growth and is
responsible for the bacteriostatic action of the quinolones [64].
1.5 Important structural features of antibacterial quinolones
The essential structural features for a quinolone based molecule to show
antibacterial activity is shown in Figure 1-7.
Position J: This position forms part of the enzyme-DNA binding complex [65].
Small, saturated or unsaturated, alkyl moieties enhance the antibacterial action
especially against Gram negative microbes [66]. Cyclopropyl substitution is the
most potel1lsubstitution at this position [67].
16
CII"pterl-Quillo/mre.l\:Allfwerview
Figure 1-6: DNA gyrase super coiling cycle showing the point of action of quinolones
Figure 1-7: General structure of most commonly used quinolone molecules.
17
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Replacing the alkyVaryl substitution at N-l position by an alkyl-aryl methyl moiety was
found to decrease antibacterial activity against Gram negatives while it increased the
activity against Gram positive bacteria [68]. It was also found that replacing the hydrogen
atoms on the N-I substituents by fluorine atoms preserved the activity [69]. Based on
these studies, the 2,4-ditluorophenyl moiety is considered as the second important
substitution required for antimicrobial activity of qui no lones[67].
Position 2: In thepre-tluoroquinolone era, addition of various substituents at this position
has been shown to diminish antimicrobial activity [70]. This position is close to the
gyrase binding site. Bulky substitution at this position inhibits thetransportofquinolones
across the bacterial cells and leads to diminished antimicrobial activity [65]. However,
when sulfur is incorporated in a small ring, it can replace the hydrogen without adversely
affecting the activity [65]. Norfloxacin analogues prepared by the bioisosteric
replacement of C-2-CH by N, ware found to have comparable activity. However, their
potency was found to be reduced significantly. Comparative MIC values are shown in
Table I-I [71,72].
Drug MIC(~lg/ml)
against£. Coli
Norfloxacin CH 0.1
3.13
Table I-I: MIC ofC-2 variants
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Position 3 and 4: Position 3 and 4 are responsible for gyrase binding and bacterial
transport. A carboxyl substitution is found to be superior to the esters, phosphonates and
sulphonates[73]. Fusing a thiazolidone ring betweenC-2 and C-3 ofquinolones,because
of its aromatic resonance, can mimic the carboxyl group and resultedincompoundswith
outstanding ill vitro potencies. Comparative MIC values against various bacterial strains
are shown in Table 1-2[74-76].
Structure
E.coli
MIC(~g!ml)
P. aerllginosa Sallrells
DNAgyraselCso
(~lg!ml)
Ciprotloxacin 0.004
0.005
0.125
0.02
0.25
0.02
0.3
0.09
Table 1-2: MIC ofC-3 variants
Position 5: Substituents present in this position must not be big and they should be able to
form hydrogen bond with the DNA, for increased potency [77]. Introduction of a primary
amine substitution at C-5 was found to increase the antimicrobial activity against E. coli
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[77]. Other electron donating groups such as hydroxyl, methyl etc., were also found to
increase ill vilro activity against gram-positive bacteria as shown in Table 1-3 [78].
F~C1.l0HH2N~~~J
S F I
MIC(llg/l11l) lor:
£.co!i P. aerl/ginosa Sal/rel/s
NH2 0.025 0.\ 0.05
OH 1.56 6.25 1.56
0.78 3.\3 3.13
Table 1-3: MIC ofC-5 variants
Positioll 6: Fluorine substitution at this position has been found to markedly increase the
anti- bacterial activity as shown in Table 1-4, and has resulted in the modem day
tluoroquinolones [66]. Ledoussal el al. [79] found that replacement of an hydrogen at the
6th position with tluorine has resulted in analogues with better activity.
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MIC(pg/ml) lor:
£.coli P.aemginosa
0.78 3.13
0.05 0.39
Table 1-4: MIC ofC-6 variants
Position 7: Substituents at this position are responsible for controlling potency and
pharmacokinetics. This position directly interacts with the DNA gyrase [80]. Five- or six-
membered nitrogen heterocycles are generally present at this position.
PositionS: Substituent at position 8 has also been shown to control pharmacokinetics,
spectrum of activity and reducing the development of bacterial I'esistance[82].Alkylation
at this position has not only been shown to increase activity against Gram positive
bacteria,butitalsoimprovesoverallpharmacokineticparameters.
1.6 Non classical useofquinolones
1.6.1 Quinolones as Antitumor agents
Cancerouscellsdivideandmultiplyatamuchfasterratethanthatof normal cells.
Topoisomerase is a key enzyme in DNA replication which is responsible for cleaving the
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D A chain at specific locations to relieve the strain of the growing replication fork and
resealing the cleaved strains afierwards. Inhibition of this key enzyme causes hindrance
with the proper functioning of cell machinery and eventually leads to arrest of the cell
cycle. Many topoisomerase directed cytotoxic agents are based on this principle [84].
Topoisomerase II is an eukaryotic analogue of the D A gyrase enzyme. Many
compounds like teniposide, etoposide, adriamycin, m-ASA etc., target Topoisomerase II
to exert their cytotoxic profile [84]. DNA intercalating agents, which are well established
in lhe treatment of cancer, are also known to cause DNA damage as a mode of their
cytotoxic action [84-85]. Various studies have revealed that topoisomerases are involved
in mediating the effect of various cytotoxic drugs, including DNA intercalating agents
[84-85].
Quinolones are well known for their antibacterial activity and they cause
excessive chromosomal damage within the bacterial cells [86, 87]. In a separate study, it
was found that fonnation of the gyrase-D A complexes leads to exposure of extra
quinolone binding pockets which plays a significant role in D A damage [88]. Although
many well known quinolones show a high degree of specificity towards either bacterial or
cukaryotic Topoisomerase enzymes, since both enzymes are homologues and share
mechanistic similarity, there is high possibility of interaction with both enzymes by some
compounds. Indeed, several antibacterial quinolones that inhibit P4 DNA- unknotting
activity of various eukaryotic Type -II Topoisomerase have been identified [89, 90].
Kohlbrenner et al. [91] reported two novel antibacterial isothiazoloquinolones, A-
65281 and A- 65282 (Figure 1-8) as potent inhibitors of both bacterial and eukaryolic
Topoisomerase enzymes. These compounds were shown to induce D A breakage as well
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as to inhibit the P4- unknotting reaction catalyzed by calf thymus Topoisomerase II. In
this study, a new class of Topoisomerase II directed compounds, which were able to
interact with both bacterial and eukaryoticenzymes, were discovered.
Robinson et al. [92] reported CP-115,953 which displayed double potency of that of
etoposide at enhancing Topoisomerase II, mediated DNA cleavage. When the
cyclopropyl group was replaced with an ethyl group at N-I position, potency was found
to be reduced by 20%. Compound WfN 57294 [93], A-62176 [94], and A-85226 [95]
were also found out to be effective against cancer cell growth. Compound A-65282 which
isan isothiazoloquinolone derivative was having comparable potency with teniposide in
enhancing Topoisomerase II-facilitated DNA breakage. Compound WfN 57294 which is
a 7-(2,6-dimethyl-4-pyridyl) derivative was found to have an EC jo value of 7.6 flM in a
DNA cleavage assay using HeLa Topoisomerase II. Compound A-62176 and A-85226
were found to have a broad activity against human and murine tumour cell lines.
Compound AG-7352 [96] was also found to be more cytotoxic against human cell lines
compared to etoposide.
Signal transducers and activators of transcription (STATs) area group of proteins
which are primarily responsible for modulation of signal transcription in the cell.
Vinkemeier et al. [97] have detined them as "A tamily of transcription factors that are
specifically activated to regulate gene transcription when cells encounter cytokine and
other growth tactors". Out of seven different subtypes of mammalian STAT protein.
STAT3 has achieved an important position in anti cancer therapy [98].
A high throughput screening [99] was conducted recently on a large number of
compounds and it was found that a compound which was a highly fluorinatedquinolone
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derivative, inhibited STAT3 pathway and eventually caused cell apoptosis (ECso =
4.6~IM). Further optimisation of structure of this fluorinated compound resulted in a 30-
fold increase in STAT3 pathway inhibitory potency [99]. Following these encouraging
results, a receptor based virtual screening was perfomled on nearly 70,000 different
compounds. The results have identitieda few 3-carboxy-4(IH)-quinolones as very potent
human protein kinase CK2 inhibitors [100]. Protein kinase CK2 plays an important role in
development of some types of cancer. They have also been shown to play an important
role in viral infection and inflammatory failures. From this point of view, quinolonescan
not only be considered as potential anticancer agents but also anti-infectiousandanti-
inflammatory agents. The chemical structures of the above compounds are depicted in
Figure 1-8.
DW""OCOOHI ~ IHO I: F I
Figure 1-8: Novel quinolonederivatives having anticancer activity
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1.6.2 Quinolones as Anxiolytic agents
Seligman et al. [101] have defined anxiety as a psychological and physiological
state characterized by somatic, emotional, cognitive, and behavioural components. y-
Aminobutyric acid (GABA) is one of the most important inhibitory neurotransmitters in
the central nervous system. It exerts its effects by acting primarily on GABA receptors.
The GABA;\ receptor is a pentameric macromolecular complex that regulates the opening
and closing of ligand-gated chloride ion channels. GABA;\ receptors in humans are made
up of six typesofa subunits, three different typesofBand y subunitsaswellasaoand8
subunits. Each of these subunits are responsible for different physiological effects (al-
containing receptors are involved in sedation, a2 and a3 in anxiolytic activity) [102]. The
benzodiazepine class of drugs has been widely used as anti-anxiety agents. They
generally show no selectivity against the receptor on which they act and allosterically
modulate the GABA-mediated chloride ion influx through the chloride ion channel.
However, benzodiazepinesareassociated with a considerable amount of undesirable side
effects. This problem has led the search for finding betteranxiolytic agents.
Kahnberg et al. [103] found out that 3-ethoxycarbonyl-6-trilluoromethyl-4-quinolone
(15) is a very interesting lead compound for developing molecules that can effectively
bind at the benzodiazepine site ofGABA;\ receptors. Further lead optimisation of this
compound led to a large number of novel molecules that were able to bind to GABA;\
receptors with very high affinity. Binding affinities for the compounds \6-\9 were found
to be in the sub-nanomolarrange. However, in this study, only compounds 20-22 were
tested on the atB2Y2s and a3B2Y2s GABA;\ receptor subtypes. Compound 2\ and 22 were
lound to be selective for at vs. a3-containing receptors. The K; ratio for compounds 2\
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and 22 was found to be 22 and 27, respectively. These values for receptor selectively
ware found comparable to that of the well known UI subunit selective dmg, Zolpidem.
Structures of compounds 15-22 are shown in Figure 1-9.
15 CH2CH3 CF3 0
16 CH2CH2CH3 CH2C6Hs 0
17 CH2CH2CH2CH3 CH2CH3 NH
18 CH2CH2CH3 CH2CH3 NH
19 CH2CH2CH3 CH2C6Hs NH
20 CH2CH3 Sr 0
21 CH2CH2CH(CH3h CH2CH3 0
22 CH2CH3 CH2C6Hs 0
Figure 1-9: Novel quinolonederivatives with anti-anxiety effect
1.6.3 QlIinolonesas Antiviral agents
1.6.3.1 Qninolones as Anti-HSV-I agents
Oral and facial lesions in humans are mainly caused by Herpes Simplex Virus
type I (HSV-I). Although, Acyclovir is available for use in the chemotherapy for these
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lesions, development of resistance against the effect of acyclovir in immuno-
compromised patients is often a problem. Recent works on discovering qui no lone-based
derivatives that can be used in HSY-l infection led to the identification of compound 23
(Figure 1-10). It is a quinolone acyclonucleoside derivative having high activity against
HSY-1(104]. Most of the synthesized derivatives were effective in reducing the viral load
in the range 01'70-99% at the concentration 01'50 ~M. It was also discovered that acidic
dcrivativesofquinolones were more effective than theircolTespondingestercounterparts.
Compounds 23a-d were also tested for cytotoxicity in Yero cells. Many novel quinolone
derivatives were effective in preventing the cylophatic effect of HSY-I at micromolar
concentrations. Compound 23b was found to be the most effective anti-HSY-I derivative
withapotencythatwas 1.5-foldofacyclovir.
Further screening was performed on these compounds and a naphthalene
carboxamide was identified as a non-nucleoside inhibitor of human cytomegalovims
(HCMY) polymerase. P U-183792 (Figure I-II) was found to be a competitive
inhibitor of herpes virus polymerase that was effective against both human and animal
herpes viruses. However, when toxicity assays were perfomled on PNU-183792 using
four different mammalian cell lines, it was not found to be cytotoxic at relevant drug
concentrations (CC50 value> IOO~M).
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H3CWOCOOH
I"': I
~ N
~CH3
Figure 1-10: Structure of Acyclovir and compound 23
Figure I-II: StructureofPNU-183792
1.6.3.2 Quinolonesas HIV-I Inhibitors
Current chemotherapy for the treatment of HIV infection is endowed with many
shortcomings which include emergence of resistant strains and inability of current
treatment regimens to completely eradicate viral infection. This has led to the search for
novel molecules possessing new mechanisms of action which might be able to overcome
the current shortcomings. One of the crucial steps in viral replication is the transcription
of its genome into mRNA. Inhibitors of this step will be able to suppress HIV replication
in both acutely as well as chronically infected cells [105]. It was discovered by Babaand
coworkers that some antibacterial l1uoroquinolones can also exhibit antiviral activity.
Two analogues, K-37 and K-38 (Figure 1-12), having a 3,4-dehydro-4-phenyl-l-
piperidinyl moiety at the C-7 position, exhibited ECso < 50 nM in chronically infected
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cells. Cecchetti and coworkers [106] began study on various quinolone derivatives
including 6-tluoroquinolones and 6-destluoroquinolones and discovered that 6-amino-l-
lert-butyl-7-[4-(pyridin-2-yl)]-I-piperazinyl-4-oxo-I,4-dihydroquinoline-3-carboxylic
acid exhibited good antiviral activity and was taken as the lead molecule. To establish the
stlUctureactivityrelationshipsofthislead,aseriesofvariouslysubstitutedmolecules
were synthesized. Among those molecules, Compound 24 (Figure 1-8), which has a
methyl substitution at the N- position and a 4-(2-pyridinyl)-I-piperazine moiety at
position 7, was found to be the most potent compound with EC50 = 0.1 ~IM.
Figure 1-12: StmctureofK-37, K-38 and compound 24
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1.6.3.3 Quinolones as HIV-I Integrase Inhibitor
HIV-llntegrase(1 )isaviralenzymethatisresponsiblefortheinsertionofviral
cD A into the genome of the host cell. It is one of the three most essential enzymes,
encoded by the viral genome, and plays an important role in viral survival [107]. There
are two different steps involved in the insertion reaction catalyzed by I . The first step
takes place in the host cell cytoplasm where IN cleaves GT nucleotides from the DNA
conserved 3'-CAGT end. This reaction is also known as 3' processing and results in
unprotected hydroxyl groups at the both 3' ends of viral cDNA. The enzyme along with
processed viral cDNA then moves to the nucleus of the host cell where the second
reaction takes place. In the second stage of the integration, IN catalyzes the nucleophilic
attack of both 3'-end hydroxyls of the viral cDNA onto the host DNA. This process is also
known as the strand transfer reaction.
The Diketo acid (DKA) class of IN inhibitors were once milestones for the
inhibition of I . Raltegravir has shown a wide spectrum of activity as an IN inhibitor.
GS-9137 (Figure 1-13) [108], a derivative of4-quinolone-3-carboxylic acid, is effective
asanlN inhibitor, and is currently under clinical evaluation [109].
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?dr"",,,CI~ F 0 COOHI""'" It 3 ~IYCH3
OH CH3
Figure 1-13: StructureofGS-9137 and Raltegravir
1.6.4 Quinolones as Anti-Ischemic Agents
Ischemic cell injury, in many cases, is responsible for fatality or life-long
disability. The most common treatment for ischemic cell injury relies on the use of
thrombolytic therapy, which restores blood flow to the ischemic region. However,
thrombolytic therapy has its own limitations. Recently, studies conducted on known
amibiotics have found them to be potential anti-ischemic agents. Antibiotics can inhibit
inflammation and/or infection associated with ischemia; hence they Cill1 be regarded to
have a potential role as anti-ischemic agents. [110]. In a study published by Parke/a/..
ciprofloxacin exhibited ill vivo and ill vitro anti-ischemic activity. Lead optimization
study, on various known and novel molecules, with an aim to separate anti-ischemic
activity from the anti-bacterial activity, resulted in the discovery of compound SQ-4004.
This compound exhibited potent cell viability with reduced anti-bacterial activity.
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SQ-4004 has also shown neuroprotective as well as cardioprotective effects (Figure 1-
14)[110].
Ciprotloxacin
H0COOH
rN)lA)
HN~ ~
SQ-4004
Figure 1-14: Structure ofCiprotloxacin and SQ-4004
1.7 Conclusion
The quinolone molecule is one of the most promising scaffold which can be
modified in a number of ways to achieve diverse phamlacological activity. These
activities can range from being antibacterial, anti-ischemic, antitumour, antiviral.
Despite great progress towards improving their antibacterial profile, they are still a hot
topic of antibacterial research, mainly because of development of resistant bacterial
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CHAPTER 2
Polycyclic Quinolones: Design, Synthesis,
Preliminary in vitro and in silieo study.
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2.1 Introduction
Quinoline derivatives form a major class of heterocycles. Thequinolone nucleus
is present ina diverse range ofbioactive molecules, most important being antibacterial
agents. Many quinolone-based antibiotics were introduced and later withdrawn from the
market, mainly because of development of bacterial resistance towards them.
It was discovered that non-tluorinated quinolones have better activity against
resistant species [1-5]. Compound PGE 9262932 and PGE 9509924 reported by Jones el
al. [3] were found to have good activity especially against antibacterial resistant strains
(Figure 2-1).
Figure 2-1: Structure of PGE 9262932 and PGE 9509924
Our research group has long been involved in developing a novel series of
polycyclic quinolones with diverse biological activities [6a-c]. In the search lor novel
polycyclicquinolones with potential antibacterial activity, a patent by Katsumi etal. [7]
was of interest. In their report, compound A was mentioned as a molecule with a good
antibacterial profile (Figure 2-2). This compound was a tluorinated derivative of a
polycyclic quinolone. Based on the data, that the non-fluorinated quinolone derivatives
aremoreeffectiveagainstresistantbacterialspecies,weattemptedthedesign,synthesize
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and evaluation of various non-fluorinated analogues of compoundA.lnthiscontext,our
research was focussed on the syntheses ofO-and N-alkylatedanalogues.
Figure 2-2: Structure of Compound A (Patent by Katsumi el ill. [7])
2.2 Material and Methods
2.2.1 0- Alkylated quinolones
In our synthetic approach, 3-fluorophenylisothiocyanate was used as the main
starting material which, upon reaction with diethyl malonate and sodium hydride in
tetrahydrofuran, afforded the salt 1. This salt was allowed to react with iodomethane to
obtain compound 2. This compound was immediately subjected to thermal cyclization
under vacuum to afford compound 3 in 47% yield [6,8] as shown in Scheme 2-1.
Following the alkylation procedures reported by Garlapati, R. el al. [6a] and
Hassan A el al. [9] with minor modifications, compound 3 was allowed to react with
ethyl bromide and benzyl bromide to give compounds 4a and 4b, as depicted in Scheme
2-2.
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("'1 N"S' ''',' CltOOCXCOOEt~ ~_COOEt -"-',h.... I ~ CH
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F 19J"/o
NH 10Et 27Cf/oNH S"""
Scheme 2-1: Synthesis of compound 3
Scheme 2-2: Synthesis of compound 4a and 4b
According to the procedures reported by Garlapati, R. etal. [6a] and Venkatesh,
C. et £II. [10] with minor modifications, compound 4a was subjected to oxidation using 111-
chloroperoxybenzoic acid to give Sa. A five-membered ring containing sulfur as
heteroatom, was incorporated in compound Sa by reacting it with ethyl mercaptoacetate
in presence of triethylamine as a catalyst to give compound 6a, following the conditions
reported in references [6a], [11-13] with minor modifications. (Scheme 2-3).
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Scheme 2-3: Synthesisofcompound6a
The same conditions as those used in the conversion of compound 4a t06a were applied
to compound 4b to obtain compound 5b, as shown in Scheme 2-4.
Scheme 2-4: Synthesisofcompound6b
Following the procedures reported by Tabart, M. el at. [14], Antoine, M. el al.
[15], and Massari, S. elal. [16] with minor modifications, nucleophilic substitution was
caITied out on compounds 6a-b using various substituted amines to yield the final
products 7a-h as depicted in Scheme 2-5. Compounds 3, 4a, 4b, Sa, 5b, 6a, 6b have also
beenpreparedbyourresearchgroup,previouslyasapartofadifferent project [6a]
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Scheme2-5:Synthesisofcompound7a-h
2.2.2 N- Alkylated quinolones
In this approach. 2,4-dichlorobenzoylchloride was used a starting material for the
preparation of N-alkylated derivatives. This compound was reacted with potassium ethyl
malonate, magnesium chloride and triethyl amine to afford compound 8 as a ~ keto ester,
following the conditions reported in references [6a], [17] with minor modifications.
(Scheme 2-6).
Scheme 2-6: Preparation or~ keto ester, 8
The ~ keto ester derivative 8 was allowed to react with ethyl or benzyl isothiocyanate in
the presence of potassium hydroxide and II-tetrabutylammonium bromide as catalyst to
afford compounds 9a and 9b, respectively. Compound 9a and 9b, being unstable open
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ring molecules, were immediately subjected to cyclization using I-BuOk to afford
compounds lOa and lOb, respectively, following the conditions reported in references
[6a]and[17] with minor modifications. (Scheme 2-7).
Compound lOa was subjected to oxidation using lIl-chloroperoxybenzoic acid to
give Ila following the conditions reported in references 16a] and [10] with minor
modifications. A five-membered ring containing sulluras heteroatom, was incorporated
into compound Ilabyreacting it with ethyl mercaptoacetate in presenceoftri ethylamine
as catalyst to give compound 12a following the reaction conditions reported in references
[6]and[II-I3] with minor modifications. (Scheme 2-8).
The same conditions as those used in the conversion of compound lOa to Ilaand
12 a were applied to compounds lOb and lIb to obtain compound 12b, as shown in
Scheme 2-9.
Nucleophillic substitution was carried out on compounds l2a-b using various
substituted amines to yield the final products l3a-h (Scheme 2-10) following the
conditions reported in references [14-16] with minor modifications. Compounds lOa,
lOb, Ila, lIb, 12a, 12b have also been previously prepared by our research group, as a
part of different project [6a].
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~COOEt
°dJl~,
Scheme 2-7: Synthesis of compound IOa-b
Scheme 2-8: Synthesis of compound 12a
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Scheme 2-9: Synthesis of compound I2b
~HCOOEI
cl)lAr)L?-
______ ~H COOEt
xAAr)LsY
Scheme 2-10: Synthesis of compound 13a-h
2.2.3 III vitro microbiological testing
Antimicrobial screening of the synthesized compounds 7a-1I and l3a-1I was carried out
using the Broth dilution method to detennine their minimum inhibitOly concentration
(MlC). The 96-well microtitreplate-based serial dilution checkerboard method was
adopted [18]. Mueller Hinton broth was used as a liquid medium for sensitivity test. In
57
Chapter 1- Po/yc:rclic Qllillo/mres: des~t.:II. ~:rllthesis. prelimillary ill vitro alld ill silieo .\·(lIl~V.
accordance with the protocols followed by TaMan Laboratory, Nalidixic acid and
Rilampicins were used as controls and £. coli, M. Iwelles, S. epider/llidis, I\;/. seg/llenlis
were used as the test organisms. Stock solution of concentration 10000 11M was made
using the appropriate weight of test compounds. 100111 of sterile media was added to the
well IA-IH (Figure 2-3). To the wells 2A-2H to IIA-IIH. 50 III of sterile media was
added. To each well IA-IH, 2 III of the stock solution of test compound was added and
mixed properly. Using a multichannel pipette. 50 III of the media from wells IA-I H was
transferred to the wells 2A-2H and mixed properly. This procedure was repeated till the
wells IIA-IIH. To the wells 12A-12H, only 50 ~d of the sterile media was added without
any test compound. To each well, 50 III of various microbial suspensions was then added.
This resulted in the effective concentrations of 100, 50, 25,12.5,6.25,3.125,1.5625,
0.7812.0.3906. 0.1953 and 0.0976 11M in the wells I-II, respectively. Wells were then
allowed to incubate at the respective temperature. Plates containing M. IlIlells was
incubated at 30ue for 48 hours. Plates containing Mycohaclerill/n s/lleg/llalic and £. coli
were incubated at 37uC. Similarly, SlaphylococclIs epideder/llis was incubated at 3i1e for
48 hours. Rifampicin and Nalidixic acid were used as the reference standards. After
incubation, plates were observed visually to detect the presence of bacterial growth.
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Figure 2-3: A 96 well plate
2.3 MoleeularDocking
2.3.1 Methods
DNA gyrase + DNA model was generated by superposition onto the
crystal structure of the topoisomerase IV (pdb code 3FOF). Chains A and B from 31FZ
were superimposed to the corresponding chains from 3FOF, respectively, and the DNA
structure from topoisomerase IV was exported to the DNA gyrase structure. Docking
calculations were carried out according to the Docking Server methodology [19]. The
MMFF94 force field [20] was used for energy minimization of ligand molecule using
DockingServer. PM6 semi-empirical charges calculated by MOPAC2009 were added to
the ligand atoms. Non-polar hydrogen atoms were merged, and rotatable bonds were
defined. Docking calculations were carried out on Mycohacleri/lll1 Illherclllosi.\· DNA
gyrase structure with the pdb code 31FZ, the constructed 3IFZ+DNA model and
Escherichia coli DNA gyrase subunit B (PDB entry: IEII). Essential hydrogen atoms,
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Kollman united atom type charges, and solvation parameters were added with the aid of
AutoDock tools [21]. Affinity (grid) maps with 80x80x80 A and 25x25 x25 A dimension
(blind and focused docking, respectively) and 0.375 A spacing were generated using the
Autogrid program [21]. AutoDock parameter set- and distance-dependent dielectric
functions were used in the calculation of the van der Waals and the electrostatic tenns,
respectively. Docking simulations were perfomled using the Lamarckian genetic
algorithm (LGA) and the Solis & Wets local search method [22]. Initial position,
orientation, and torsions of the ligand molecules were set randomly. Each docking
experiment was derived li'om 100 different runs that were set to tenninate after a
maximum of 2500000 energy evaluations. The population size was set to 150. During the
search. a translational step of 0.2 A,and quaternionand torsion steps 01'5 were applied.
2.3.2 Docking calculations to GyrA region of Mycobacterium tuberculosis DNA
gyrase
2.3.2.1 Background and availability of the models
Mycobacterium tuberculusis DNA gyrase is an important target protein against
multidrug-resistant tuberculosis. There are two deposited structures of this DNA gyrase.
The GyrA N-tenninal domain from Mycobacterium tuberculusis X-ray structures
available in Protein Data Bank are 31FZ and 31LW (Table 2-1).
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Table 2-1: Available X-Ray structures of ON A gyrase GyrA N-temlinal domain from
Mycobacterium tuberculosis
The structure of POB entry 31LW has been resolved with higher resolution,
however, 31FZ structure covers the whole N-terminal region and more importantly, it was
determined as a complex with a bound ligand «4S)-2-methyl-2,4-pentanediol). Therefore,
POB entry 31FZ seems to be a more adequate target than that of 31LW to carry out
dockingcalculations.ltis important to note that the structureofa homologous protein,
ONA topoisomerase IV complexed with ONA and quinolone is also available (POB
entry: 3FOF). This structure reveals that the quinolone is intercalated at the highly bent
ONA gate. Therefore, a binding site composed by ONA gyrase and ONA should be also
considered.
2.3.2.2 Blind Docking Experiment
Three ligands, compound 13'1, compound 7'1 and compound A, (Page 51, Figure
2-2), were docked to ONA gyrase. A blind docking calculation covering the whole
protein structure (POB entry: 3IFZ) was carried out to identify possible binding sites. In a
secondstep,ligandsweredockedtoi)thesiteidentifiedintheblind docking calculations,
ii) to the ligand binding site of31FZ and iii) to a constructed ONA gyrase-ONA complex.
The calculated docking energies are summarized in Table 2-2.
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Compound/docking type blind focused focused2 c~Np~ex
Compound 13a -7.74 -8.02 -7.14 -9.85
Compound7a -7.72 -8.26 -7.06 -9.69
Compound A -8.91 -9.1 -7.47 -9.95
Table 2-2: Calculated docking energies in kcaVmol
In order to define possible binding sites in the protein, Mycobacterium tuberculosis DNA
gyrase, blind docking procedure was applied. According to our calculations, all
compounds were docked to Potential Binding Site 1. (Figure 2-4). Therefore, this site was
selected for focused docking calculations. It is important to note that buried binding sites
cannot be identified by blind docking. Therefore, the binding site of (4S)-2-methyl-2,4-
pentanediol (Potential Binding Site II., Figure 2-4) was also selected for focused docking
calculations.
Figure 2-4: Potential binding sites ofPDB entry 3IFZ
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2.3.2.3 Focused Docking Experiment
Compound A, as well as compounds 13a and 7a were subjected to focused
docking calculations at the potential binding site I of the protein. The docking geometries
and interactions are shown in Figure 2-5.
Figure 2-5: Docked structure of compound A at potential binding site I and calculated
interactions of the docked compounds (HB: hydrogen bond, PO: polar, HY: hydrophobic,
CA: cation-pi, OT: other)
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As the results show, the investigated compounds form similar interactions with the
protein. As can be seen in Figure 2-5 and the corresponding interactionta ble,thedocked
compounds are bound with many specific interactions. Compound A forms strong
hydrogen bonds (or Coulomb interaction) with ASPl22 and ASP281, additionally
Ser118, Ser306and ASP304are involved a halogen bond. While there are many polar
interactions involved in ligand binding, the number of hydrophobic residues and
consequently hydrophobic interactions is very limited at potential binding site I.
Therefore, the planar aromatic ring is not involved in specific interactions. The absence of
the specific hydrophobic interactions can hinder ligand binding to this site in vitro.
In the next step, compound A,compounds 13aand 7aweresubjectedto focused docking
calculations at the potential binding site II of the protein. The docking geometries and
interactions are shown in Figure 2-6.
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ARG98POOT
A$Nl72PO OT
GlY47HB
SER104PQQT
Figure 2-6: Docked structure of compound A at potential binding site II and calculated
interactions of the docked compounds (HB: hydrogen bond, po: polar, HY: hydrophobic,
CA: cation-pi, HA: halogene bond, OT: other)
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In contrast to potential binding site I, many hydrophobic residues fornl
hydrophobic interactions at potential binding site II (TRPI03, TYR276, LEU48, MET99),
however, the number of polar interactions is limited at this site. No specific hydrogen
bonds can be found for compound A, additionally, there is no interaction partner for the
quaternary nitrogen. Therefore, the calculated docking energies for this site are higher
than that of potential binding site I.
As it was mentioned earlier, the stmcture of a homologous protein, DNA
topoisomerase IV complexed with DNA and quinolone is also available (PDB entry:
3FOF). This stmctures reveals quinolone intercalated at the DNA gate. Therefore, we
constructed a model for DNA gyrase-DNA complex, and focused docking calculations
were carried out to the interaction interface. Figure 2-7 shows compound A docked to
this potential binding site. The charged quaternary nitrogen forms strong Coulomb
interaction with ASP89 and hydrogen bond with HIS87. The planar aromatic ring is
intercalated in the DNA structure. This interaction is ideal for both the hydrophilic and
hydrophobicpartsoftheinvestigatedcompounds;dockingenergies were calculated to be
the lowest at this potential site.
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Figure 2-7: Compound A docked to DNA gyrase-DNA complex
2.4 Background and availability of the models
The structure of DNA gyrase subunite B (gyrB) from Mycobacterium
tuberculosis DNA gyrase subunit B is only known in the 448-675 sequence region (PDB
entries: 3M4I, 3IGO, 2ZJT). This region does not include the ATP binding region and
therefore cannot be used for docking calculations. The ATP binding region of
Escherichia coli DNA gyrase subunit B is determined (PDB entry: IEIl). The sequence
alignment of Mycobacterium tuberculosis DNA gyrase subunit B and Escherichia coli
DNA gyrase subunit B is shown in Figure 2-8.
67
Chapter 2- Polycyclic Quin%nes: design, synthesis, preliminary in vitro and in si/ico study.
:~~~~:=:::'co~ ~:: :~::: ~~~~~~~~;g~~r.~~~Z;~~~~~~;:~~g~~~z~~~~:t~~~~~~~~~~~~~~~~~
:~~~~:=::~~ ~:: :~::: ~:I~~;~~~~~;:~~eZ.~~~*~~~:Z~~~Z~~e:~:'C:;~;=;o~;~:~e:,,~;
POCSCSIG'tRB_MYCTODNAqyra•• LKQGAPTKKTGSTVRfWADPAVFE-TTEYDfETVARRLQEMAFLNKGLTINLTOERVTOOEWDEWSDVAEAPKSASER
POAES61G'tRB_EOOLIDNAgyr... LAVTGETEKTGTMVRfWPSLETfTNVTEFEyEILAKRLRELSFLNSGVSIRLRDKRDGKED-------------------
POC5CSIG'tRB_NrCTODNAgyra.. AAESTAPHKVKSRTFHYPGGLVDFVKHINRTKNAIHSSIVDFSGKGTGHEVEIAMQWNAGYSESVHTFANTINTHEGGTH
POnS6IGYRB_ECOLIDNAqyr... -------------HFHYEGGlKAFVEYLNKNKTPIHPNIFYFST£KOGIGVEVALQWNDGFQENIYCFTNNIPQRDGGTH
POCSC51G'tRB_NYCTODHkqyra.. EANPTOAKVVVNKAVSSAOARIAARKARELVRRKSATOIGGLPGKLADCRSTOPRKSELYW£GDSAGGSAKSGROSMF
POAES61G'tRB_ECOLIOHA'lYr... LENPTOAKIWGKIIDAARAREAARRAREMTRRlI:GALOLAGLPGKLADCOEROPALSELYLVEGOSAGGSAK RNRKNQ
POCSCSIGYRB_NYCTODHAqyr••• AILPLRGKIINVEKARIDRVLKNTEVQAIITALGTGIH-DEFDIGKLRYHKIVLMADADVDGQHISTLLLTLLFRFMRPL
POAES6IGYRB_ECX>LIDHAqyr••• AILPLKGKILNVEKARFDKMLSSQEVATLITALGCGIGROEYNPOKLRYHSIIIMTDADVDGSHIRTLLLTFFYRQMPEI
POC5C5IGYRB_NYCTODHAqyr IENGHVfLAQPPLYKLK
POAES6IGYRB_I:CX>LIDHAqyr VERGHVYIAQPPLYKVK
Figure 2-8: Sequence alignment of Mycobacterium tuberculosis DNA gyrase subunit B
and Escherichia coli DNA gyrase subunit B (ATP binding site residues are shaded with
red color)
2.5 Docking calculations to GyrB region of Escherichia coli DNA gyrase
The ATP binding region (Figure 2-8) is identical for the two species expcept the
sole valine/isoleucine conservative change. This high sequence identity allows us to carry
out docking calculations on Escherichia coli DNA gyrase subunit B (PDB entry 1EIl).
2.5.1 Focused Docking Experiment
Due to the closet structural similarity of compound 13a and 7a with compound A,
they were chosen for docking calculations. Docking calculations were carried out to the
known ATP binding site. The calculated docking energies of compound A, compounds
13a and 7a to gyrB shows strong potential binding (-9.73 kcaVmol, -9.06 kcaVmol, -8.27
kcaVmol, respectively). The compounds were docked in a similar conformation to the
ATP binding site of gyrB (Figure 2-10). The lowest energy docking result for compound
A is shown in Figure 2-9.
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VAl71HBHYOT YAl.71HBHYOl
VAlllHBOT
Figure 2-9: Docked structure of compound A at ATP binding site and calculated
interactions of the docked compounds (HB: hydrogen bond, PO: polar, HY: hydrophobic,
CA: cation-pi, HA: halogen bond, OT: other).
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Figure 2-10: Comparison of docking geometries of compound A (yellow), compounds 13a (blue)
and 7a(violet) in the ATP binding site.
The docked compounds are deeply buried in the binding site and form many
hydrophilic and hydrophobic interactions. The protonated quaternary nitrogen and ASP73
forms strong Coulomb interaction. ASP73 is also involved in halogen bonding. Similarly,
THRI65 forms a hydrogen bond with the investigated compounds and can be involved in
halogen bonding. The backbone oxygen of VAL71 donates a hydrogen bond from the
protonated nitrogen. Additionally, there are many hydrophobic interactions at the binding
site interacting with the planar aromatic ring, e.g. ILE78, ILE94, ILE41O, VAL43,
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VAL71, VALI20, VAL167 and TYRI09. These interactions and the calculated docking
energies suggest strong potential binding of the investigated compounds togyrB in vitro.
2.6 Results and discussions
2.6.1 Antimicrobial assay results
Compounds were tested against Mycobacterillm Illtelles, Mycobacterillm
\'megmatic, £. coli and StaplwlycocclIs epidedermis using Rifampicin and Nalidixic acid
as standard. Assay results against Mycobacterillm Illtelles (Table 2-3), Mycobacterillm
I"IIlegmatic (Table 2-4), £. coli (Table 2-5) and StaphalycocclIs epidedermis (Table 2-6)
are shown below.
2.6.2 Docking Result
The GyrA region of bacterial topoisomerase forms a complex with DNA and
carries out its function. Quinolones interact with this DNA-GyrA complex and hence
cause inhibition of the whole complex. In our docking experiments, we found that our
standard compound A, interacts with the DNA-GyrA complex with strongest affinity as
compared to our test compounds. This is concluded as a result of lowest docking energy
of compound A with DNA-GyrA complex (Table2-2). Additionally, when compound A,
13a, 7a were docked to the ATP binding region of GyrB subunit. It was found that
Compound A has lowest docking energy (-9.73kcal/mol) as compared to our test
compounds. The main difference between the interaction of compound A and compounds
13a, 7a to our target protein is their ability to form stable complex with target proteins.
Based on the calculated docking energy, we hypothesize that these compounds might not
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be able to foml a stable complex with the target site. This may explain the lack of
antibacterial activity with compounds 13a and 7a.
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2.7 Conclusion
The quinolone based system is an excellent scaffold for design of various classes
ofbioactive molecules. Its various unique structural features have led to design and
synthesis of various diverse ranges of molecules. In this study, a series of novel non-
fluorinated polycyclic quinolones were designed based on compoundA, in order to study
the effects of absence of fluorine on its activity. These compounds were tested for their
susceptibility against Mycohacterium luteues, Mycobacterium smegmatic. £. culi and
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SlaphalycoccliS epidedermis. The test results revealed the lack of antimicrobial activity of
these compounds. In order to explore the cause behind the lack of activity, docking-
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13b >100
13c >100
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Be >100
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13g >100
13h >100 I
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Nalidixic Not I
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-experiments were carried out against DNA gyrase using "Compound A". as the standard
DNA gyrase inhibitor. Based on our docking results, we concluded that in this type of
polycyclic quinolone systems, removal of fluorine can dramatically abolish the
antimicrobial activity. This can be due to fonnation of a reversible and weak complex
with the ATP binding region of the DNA gyrase as well as with DNA-GyrA complex.
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Further structural optimisation and bioassaysofthesecompoundsto find other potential
bioactivities are ongoing in the Daneshtalabgroup.
2.8 Experimental
Solvents and reagents were obtained from commercial suppliers and were used
without further purification. Melting points are not corrected. I Hand 13C NMR spectra
were recorded on a Bruker AVANCE-500 MHz NMR spectrometer and on Bruker
AVANCE-300 MHz NMR spectrometer using tetramethylsilane as an intell1al standard.
Mass spectra were obtained on an Agilent 1100 series LC/MSD chromatographic system.
High-resolution mass spectra (EI or ESI) were obtained on Waters GCT Premier
Micromass Spectrometer. Silicycle Ultrapure silica gel (0-20 ~lIn) G and F-254 were used
lor thin-layer chromatography (TLC), and Silicycle silia-P Ultrapure Flash silica gel (40-
63 ~lIn) was used tor tlash column chromatography. TLC was conducted on Polygram
SIL G/UV254 precoated plastic sheets. The reaction yields are included in corresponding
schemes.
Ethyl 7-Fluoro-4-hydroxy-2-(methylsulfonyl)quinoline-3-carboxylate (3)
To a suspension of sodium hydride(3.655g, 145.1 mmol) in tetrahydrofuran (300
ml) maintained at 5-10 DC, diethylmalonate (23.23 g, 145.1 mmol) was added gradually
with constant stirring. The mixture was then brought to room temperature, allowed to stir
fora further 30-40 minutes and then 3-tluorophenyl isothiocyanate(22.00 g, 143.6mmol)
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was added gradually over a period of 30 minutes under ice cooling. Stirring was then
stopped and the reaction mixture was allowed to stand overnight at 4 lie. The resulting
precipitatewascollectedbyfiltrationandwashedwithdiethylether to afford compound I
as a yellow solid. The yellow solid was then dissolved in DMF (50 ml) and methyl iodide
(34.66 g, 244.2 mmol) was added gradually under ice cooling and the mixture was
allowed to stir at the 0 IIC for 2 hours. It was then slowly warnled up to room temperature
and stirred for another 4 hours. The reaction mixture was then poured into ice-water and
extracted with chloroform (25 ml x 3). The chloroform layer was separated and dried over
sodium sulfate and concentrated under vacuum to yield compound 2 as a yellow oil. This
oil was used in the next step without purification. Compound 2 was heated at 180 IIC
under vacuum lor 15-20 minutes to afford compound 3. Purification by recrystallization
fj'oma mixture of hexane and ethyl acetate(I:I) afforded compound3asawhitepowder;
mp 160-162 IIC; IH NMR (500 MHz, Chloroform-d) 8 8.09 (dd,J= 7.4, 5.0 Hz, lH), 7.61
(dd, J = 8.0, 1.5 Hz, IH), 7.21 (td, J = 7.7, 1.5 Hz, IH), 2.59 - 2.44 (m, 3H), 4.29 (q, J =
5.9 Hz, 2H), 4.04 (s, IH, OH), 1.30 (t,J= 5.9 Hz, 3H). 13C NMR (175 MHz, Chlorolorm-
d)o 176.6, 167.1. 163.1. 161.7,151.2,125.6,118.5,115.4,108.8,105.9,61.2,14.6,13.9;
HR-MS (TOFEI) calcd lor C lJ H l1 N03FS (281.0521); found (281.0521).
EthyI4-Ethoxy-7-fluoro-2-(methylsulfonyl)quinoline-3-carboxylate (4a)
To a stirred solution of compound 3 (5.00 g, 17.77 mmol) and potassium
carbonate (4.893 g, 35.4mITI01) in DMF(20 ml), (3.85 g, 35.4mmol) of ethyl bromide
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was added gradually and the reaction mixture was allowed to stir at 70-80 °c overnight.
The reaction mixture was then wanned up to the room temperature and poured into a
large quantity of cold water. The aqueous layer was extracted with chlorofonn. The
organic extract was dried over sodium sulfate and evaporated under reduced pressure to
give the cl1Jde compound 4a, which was purified by column chromatography (0.5% ethyl
acetate in Hexane) to obtain the pure compound as a yellow liquid; I H NMR (500 MHz,
Chlorofornl-d) I) 8.24 (dd, J = 7.5, 4.9 Hz, I H), 7.52 (dd, J = 8.0, 1.5 Hz, I H), 7.30 (ld, J
= 7.7, 1.6 Hz, I H), 4.29 (q, J = 5.9 Hz, 2H), 4.07 (q, J = 5.9 Hz, 2H), 2.54 (s, 3H), 1.34 (l,
J = 5.9 Hz, 3H), 1.30 (t, J = 5.9 Hz, 3H). 13C NMR (175 MHz, Chloroforl11-d) I) 169.4,
163.2,162.0,158.6,132.9,128.8,126.0,123.8, 118.7,114.3,66.4,61.2,14.6,13.9,13.8;
APCI-MS: 292.1 (M'+I).
EthyI4-(Benzyloxy)-7-fll1oro-2-(methylsl1lfonyl)ql1inoline-3-carboxylate (4b)
Utilizing the same alkylation procedure as applied for the preparationof4a using
benzyl bromide (6.05 g, 35.4 mmol); yellow liquid; I H NMR (500 MHz, Chlorofonn-d) I)
8.18 (d, J= 6.3 Hz, IH), 7.99 (dd, J= 9.1, 6.2 Hz, IH), 7.57-7.50 (m, IH), 7.47-7.39 (111,
5H), 5.16 (d, J = 4.1 Hz 2H), 4.54 (q, J = 7.1 Hz, 2H), 2.57 (s, 3H), 1.53 (t, J = 7.1 Hz,
3H); 13C NMR (175 MHz, Chlorofonn-d) I) 169.6. 165.0, 163.2, 1595. 138.8, 13·t!,
130.2,130.0,129.4,129.3,127.2,125.0,119.7, 116.2,75.5,62.4,15.8,15.1; APCI-MS:
372.1 (M"+I).
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EthyI4-(Benzyloxy)-7-fluoro-3-hydroxythienoI2,3-blquinoline-2-carboxylate (6b)
To a solution of compound 4b (1.50 g, 3.72 mmol) in dichloromethane maintained
at 0 DC, m-chloroperoxybenzoic acid(0.962 g, 5.58 mmol) was added and the reaction
mixture was allowed to stir at the same temperature for 2-3 hours. It was then warmed up
to room temperature and allowed to stir overnight. The reaction mixture was washed with
30%sodiumbicarbonatesolution(50ml)andtheorganiclayerwas separated,dried over
sodium sulfate and liltered. The filtrate was evaporated under reduced pressure to yield
compound Sb as a white amorphous solid, which was subjected to further chemical
rcaction without purification. The white amorphous precipitate obtained was suspended in
dry ethanol (30m I) and ethyl mercaptoacetate (0.60 g, 5.00 mmol,) and triethylamine
(1.51 g, 15.00 mmol) was added to it. The reaction mixture was retluxed for 5 h under
argon atmosphere. The solvent was then evaporated to dryness under reduced pressure
and ice cold water was added to the remaining mixture. The resulting mixture was
extracted with chloroform, dried over sodium sulfate and evaporated under reduced
pressure to yield compound 6b as a highly viscous yellow liquid; I H NMR (500 MHz,
Chloroform-d) (5 13.32 (s IH), 8.18 (d, J = 6.3 Hz, IH), 7.99 (dd, J = 9.1, 6.2 Hz , IH),
7.57-7.50 (m, IH), 7.47-7.39 (m, 5H), 5.16 (d, J = 4.1 Hz, 2H), 4.54 (q, J = 7.1 HZ,2H),
1.53 (t, J = 7.1 Hz, 3H). IJC NMR (175 MHz, Chloroform-d) (5 168.5, 167.0, 166.4,
165.8,164.6,159.1,154.9,137.5,129.0,128.1, 125.7, 118.9, 115.8, 115.6, 110.8, 109.9,
109.8,95.8,74.5,61.4,14.6; APCI-MS: 398.0 (M++I).
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EthyI4-(Ethoxy)-7-fluoro-3-hydroxythienoI2,3-b]quinoline-2-carboxylate (6a)
This compound was prepared by utilising the same procedure employed for the
preparation of compound 6b using compound 4a (1.17 g, 3.8 mmol); highly viscous
yellow liquid; IH NMR (500 MHz, Chlorofoml-d) 8 8.35 (dd. J = 7.5, 4.9 Hz, IH), 7.69
(dd, J = 8.0, 1.5 Hz, I H), 7.32 (td, J = 7.9, 1.4 Hz. I H), 5.86 (s, I H), 4.37 (q, J = 5.9 Hz,
2H), 4.07 (q, J = 5.9 Hz, 2H), 1.34 (t, J = 5.9 Hz, 6H). 13C NMR (175 MHz, Chlorotorm-
d) () 167.4, 166.0, 165.8, 165.4, 162.0, 154.3, 125.7, 118.0, 115.7, 111.2, 109.8, 102.4,
66.4,61.4,14.6,13.8; APCI-MS: 336.1 (M'+I)
Ethyl 4-(Ethoxy)-3-hydroxy-7-(piperazin-l-yl)thienoI2,3-bIquinoline-2-carboxylate
(7a)
To a mixture of compound 6a (0.67 g, 2.00 mmol) in DM F (10 ml), 0.86 g ( I0
mmol) of piperazine was added and the mixture was stin"ed at 110°C lor 15-18 hours. It
was then cooled down to room temperaUlre and the title compound was precipitated by
the addition of 100 ml saturated solution of sodium chloride. The precipitate wns washed
with w<tter and purilied by recrystallization from ethnnol; white powder; mp 250-252 IlC;
IH NMR (500 MHz, Chloroform-d) 0 8.20 (d, J = 7.5 Hz, I H), 7.90 (dd, J = 7.5, 1.4 Hz,
IH). 7.43 (d,J= 1.4 Hz, IH), 6.16 (s, IH), 4.37 (q,J= 5.9 Hz, 2H), 4.07 (q,J= 5.9 Hz,
2H), 3.73 (t, J = 5.1 Hz, 2H),3.39 (t, J = 5.1 Hz, 2H), 3.11 (t, J = 5.1 Hz, 2H), 3.03 (t, J =
5.1 Hz, 2H), 1.34 (t, J = 5.9 Hz, 6H), 1.23 (s,1 H). 13C NMR (175 MHz, Chlorofoml-d) 0
167.0,164.8,164.3,160.3,155.5,154.2,126.2, 118.5, 115.7, 109.8, 109.6,97.0,67.6,
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62.6,51.3,46.2, 15.8, 15.0; HR-MS (TOFEI) calcd for C~DH~3N304S (401.1410); found
(401.1409).
EthyI4-(Ethoxy)-3-hydroxy-7-(4-methylpipcrazin-l-yl)thicnoI2,3-blquinoline-2-
carboxylate (7b)
This compound was prepared utilising the procedure employed for the preparation
ofcompound7a,using(0.67g,2.00mmol)ofcompound6aandI.Og(1o mmol) of
methylpiperazine; yellow powder; mp 241-243 DC; IH NMR (500 MHz, Chlorofoml-d) 8
8.13 (d, J = 7.5 Hz, IH), 7.85 (dd, J = 7.4, 1.5 Hz, 1H), 7.37 (d, J = 1.4 Hz, I H), 4.82 (s,
IH), 4.37 (g, J = 5.9 Hz, 2H), 4.07 (g, J = 5.9 Hz, 2H), 3.44 (t, J = 5.0 Hz, 4H), 2.35 (t, J
= 5.0 Hz, 4H), 2.23 - 2.19 (m, 3H), 1.34 (t, J = 5.9 Hz, 6H). 13C NMR (175 MHz,
Chloroform-d) 0 165.8, 163.6, 163.1, 159.1,154.3, 153.0, 125.0, 117.3, 114.5, 108.6,
108.4, 95.8, 66.4,61.4, 52.6, 50.3, 46.0, 14.6, 13.8; HR-MS (TOFEI) calcd for
C~l H~5N304S (415.1564); found (415.1560).
Ethyl 4-(Ethoxy)-3-hydroxy-7-(morpholin-4-yl)thicnoI2,3-blquinolinc-2-carboxylatc
(7c)
Preparedaccordingtotheprocedureemployedforthepreparation of compound
7a,using(0.75g,2.23mmol)ofcompound6aand1.30g(IOmmol)ofmorpholine;
yellow crystals; 237-240 DC; IH NMR (500 MHz, Chlorofoml-d) 88.36 (dd. J = 7.4, 1.5
Hz, IH), 7.57 (d, J = 7.5 Hz, I H), 7.18 (d, J = 1.4 Hz, I H), 4.63 (s, IH), 4.37 (g, J = 5.9
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Hz, 2H), 4.07 (q, J = 5.9 Hz, 2H), 3.73 (t, J = 4.5 Hz, 4H), 3.27 (t, J = 4.5 Hz, 4H), 1.34
(t, J = 5.9 Hz, 6H); IJC NMR (175 MHz, ChlorofoIl11-d) S 167.2, 164.8, 164.3, 163.2,
155.5,154.2,126.2,118.7,115.7,109.8,109.6,103.6, 67.6, 67.0, 62.6, 48.3,15.8,15.0;
HR-MS (TOFEI) calcd for Cl0HllNl0SS (402.1249); found (402.1240).
Ethyl 4-(Ethoxy)-3-hydroxy-7-(pyrrolidin-l-yl)thieno12,3-bIquinoline-2-carboxylate
(7d)
Prepared utilising the procedure employed for the preparation of compound 7a,
using (0.67 g, 2 mmol) of compound 6a and 0.71 g (10 mmol) of pyrrolidine; yellow
powder; 239-242 DC; I H NMR (500 MHz, Chloroform-d) S 8.08 (d, J = 7.5 Hz, IH), 7.69
(dd, J = 7.5, 1.4 Hz, I H), 7.03 (d, J = 1.4 Hz, I H), 5.94 (s, I H, OH), 4.37 (q, J = 5.9 Hz,
2H), 4.07 (q, J = 5.9 Hz, 2H), 3.41 (ddd, J = 6.4, 4.2, 2.6 Hz, 4H), 2.09-2.01 (m,4H),
1.34 (t, J = 5.9 Hz, 6H); 13C NMR (175 MHz, ChlorofoIl11-d) 8 167.0, 164.8, 164.3,
160.3,154.6,154.2,127.1,118.5,114.7,109.8,107.3, 97.0, 67.6, 62.6, 52.3, 27.1,15.8,
15.0; HR-MS (TOFEI) calcd for CloHllNl04S (386.1300); found (386.1315).
Ethyl 4-(Benzyloxy)-3-hydroxy-7-(piperazin-l-yl)thienoI2,3-bIquinoline-2-
carboxylate (7e)
To a mixture of compound 6b (0.79 g, 2.00 mmol) in DMF (10 ml), 0.86 g (10
mmol) of piperazine was added and the mixture was stirred at 110°C for 15-18 hours. It
was the brought to room temperature and the title compound was precipitated by the
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addition of 100 ml saturated solution of sodium chloride. The precipitate was washed
with water and purified by recrystallization from ethanol; yellow solid; 248-250 °C; IH
NMR (500 MHz, Chloroform-d) 88.23 (d. J = 7.5 Hz, IH), 7.85 (dd, J = 7.5,1.4 Hz,
I H), 7.48 (dd, J = 7.5, 1.3 Hz, 2H), 7.40 (t, J = 7.4 Hz, 2H), 7.35 - 7.28 (m. 2H), 6.34 (s,
I H, OH), 5.20 (s, 2H), 4.37 (q, J = 5.9 Hz, 2H), 3.64 (t, J = 5.1 Hz, 2H), 3.43 (t, J = 5.1
Hz, 2H), 3.07 (t, J = 5.1 Hz, 2H), 2.99 (t, J = 5.1 Hz, 2H), 1.34 (t, J = 5.9 Hz, 3H), 1.24
(s, IH,); IJC NMR (175 MHz, Chloroform-d) 8 165.8, 165.3, 161.7, 159.1, 154.3,153.6,
137.5,129.0,128.2,128.1,125.0,118.4,114.5,108.4,108.2,95.8,74.5,61.4,50.1,45.0,
14.1; HR-MS (TOFEI) calcd forC25H25NJ04S (463.1565); found (463.1460).
Ethyl 4-(Benzyloxy)-3-hydroxy-7-(4-methylpiperazin-l-yl)thieno12,3-bIquinoline-2-
carboxylate (7t)
Prepared according to the procedure employed for the preparation of compound
7e, using (0.79 g, 2.00 mmol) of compound 6b and 1.0 g (10 mmol) of methylpiperazine;
white crystalline product; 241-243 °C; IH NMR (500 MHz, Chlorofollll-d) 88.31 (d. J =
7.5 Hz, IH), 7.91 (dd, J = 7.5,1.5 Hz, IH), 7.56 -7.29 (m, 6H), 5.16 (s, 2H), 4.82 (s, 1H,
OH), 4.37 (q, J = 5.9 Hz, 2H), 3.44 (t, J = 5.2 Hz, 4H), 2.35 (t, J = 5.2 Hz, 4H), 2.28 -
2.13 (m, 3H), ,1.34 (t, J = 5.9 Hz, 3H); IlC NMR (175 MHz, Chloroform-d) 8 166.8.
165.3,161.7,159.1,154.3,153.6,137.5,129.0,128.8,128.1,125.7,118.4,115.0,108.4,
108.0,95.8,74.5,61.4,52.6,50.3,46.0, 14.6; HR-MS (TOFEI) calcd for C26H27NJO.IS
(477.1722); found (477.1701).
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EthyI4-(Benzyloxy)-3-hydroxy-7-(morpholin-4-yl)thienol2,3-blquinoline-2-
carboxylate (7g)
Prepared utilising the procedure employed for the preparation of compound 7e,
using (1.18 g, 3 mmol) of compound 6b and 1.30 g (15 mmol) of morpholine; white
amorphous powder; 239-242 °C; J H NMR (500 MHz, Chlorofoml-d) 8 8.20 (d, J = 7A
Hz, I H), 7.94 (dd, J = 7.5, 1A Hz, I H), 7A8 (dd, J = 7.5, 13 Hz, 2H), 7A4 - 7.37 (m,
3H), 7.36 - 7.28 (m, 1H), 5.16 (s, 2H), 4.58 (s, 1H, OH), 4.37 (g, J = 5.9 Hz, 2H), 3.73 (t,
J = 4A Hz, 4H), 3.27 (t, J = 4A Hz, 4H), 1.34 (t, J = 5.9 Hz, 3H); 13C NMR (175 MHz,
Chloroform-d) 8 167.0.166.5,162.9.160.3,155.5.154.8.138.7.130.2. 129.3. 129.3.
126.2, 119.6, 115.7, 109.6, 109.2,97.0,75.7,67.05,62.6, 48A, 15.8; HR-MS (TOFEI)
calcd forC2sH2-lN20sS (464.1405); found (464.1401).
Ethyl 4-(Benzyloxy)-3-hydroxy-7-(pyrrolidin-I-yl)thienoI2,3-b Iqu inoline-2-
carboxylate (7h)
Prepared according the procedure employed tor the preparation of compound 7e,
using (0.80 g, 2.00 mmol) of compound 6b and 0.71 g (10 mmol) ofpyrrolidine; yellow
crystals; 230-232 °C; J H NMR (500 MHz, Chlorofoml-d) 8 8.24 (d. J = 7.5 Hz, I H), 7.82
(dd, J = 7.5, IA Hz, I H), 7A8 (dd, J = 7.5, 1.3 Hz, 2H), TAO (t, J = 7A Hz, 2H), 7.33 (dt,
J = 82, 1.9 Hz, I H), 7.16 (d, J = IA Hz, 1H), 5.18 (s, 2H), 5.02 (s, I H, OH), 4.37 (g, J =
5.9 Hz, 2H), 3AI (ddd, J = 6A, 4.2, 2.6 Hz, 4H), 2.07 - 2.0 I (m, 4H), 1.34 (t, J = 5.9 Hz,
3H); J3C NMR (175 MHz, Chloroform-d) 8 165.8. 165.3. 161.7, 159.1. 153.6. 153A.
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137.5,129.0,128.2,128.1,125.9,118.4,113.5,108.0,106.1,95.8,74.5,61.4,51.1,25.9,
14.6; HR-MS (TaFEl) calcd for C~5H~4N~04S (448.1456); found (448.1450).
Ethyl 3-(2,4-Dichlorophenyl)-3-oxopropanoate (8)
A mixture of potassium ethylmalonate (13.398 g, 76.97 mmol) and magnesium
chloride (16.415 g, 172.41 mmol) in acetonitrile was stirred under argon atmosphere for
30 min at the room temperature. Triethylamine (17.194 g, 169.92 mmol) was then added
drop wise to the reaction mixture. The mixture was continued to stir for a period of 2 h
followed by the addion of 10.9 g (52.3 mmol) of 2,4-dichlorobenzoyl chloride. The
reaction mixture was allowed to stir at the same temperature for 3-4 h. It was then
warmed up to the room temperature and I ml of triethylamine was further added to it.
The mixture was left to stir for a period of 16-18 h at room temperature. The solvent was
then removed under reduced pressure and ice cold water was added to the remaining
mixture and acidified to a pH 5-6 with hydrochloric acid. It was then extracted with three
portions of ethyl acetate (50 ml each) nnd the organic layers were combined and wnshed
with 100 ml of water followed by brine solution. Organic layer was separated out and
dried over sodium sulfate nnd evaporated under reduced pressure to give the title
compound; yellow oil; I H NMR (500 MHz, Chloroform-d) 0 7.75 (d. J = 7.5 Hz, IH),
7.64 (d, J = 1.5 Hz, IH), 7.48 (dd, J = 7.4, 1.6 Hz, I H), 4.11 (g, J = 5.9 Hz, 2H), 3.90 (s,
2H), 1.20 (t, J= 5.9 Hz, 3H); I3C NMR (175 MHz, Chloroform-d) 0195.1,168.5.139.3,
134.4,134.3,130.6,128.4,128.0,61.1,48.7,14.6; APCI-MS: 261.1 (M'+I).
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Ethyl 7-Chloro-l-ethyl-2-(methylsulfonyl)-4-oxo-1 ,4-dihydroquinoline-3-carboxylate
(lOa)
A mixture of 8 (5.00g, 19.20 mmol), potassium hydroxide (1.51g) and n-
tertbutylammonium bromide (0.007 g, 0.21 mmol) in DMF (25m I) was stirred for 30 min
at room temperature. It was then cooled to 0 DC, and to it ethyl isothiocyanate (2.90 g,
32.9 mmol) was added drop-wise under constant stirring. The reaction mixture was
allowed to stir fora period of 16-18 hat room temperature. lodomethane (3.44 g, 24.38
mmol) was then added to the reaction mixture, which was continued to stir for another 6
h. After the completion of stirring, the reaction mixture was quenched with water (IOOml)
and saturated aqueous ammonium chloride (70ml) and extracted with ethyl acetate (2 X
50ml). The organic extracts were combined and washed with water (30m I) followed by a
wash with brine (30ml) and dried over sodium sulfate. The organic phase was then
reduced to dryness under reduced pressure to give the compound 9a asa yellow liquid.
This yellow liquid was subjected to further reaction immediately, without purification.
Compound 9a was suspended in toluene (25m I) at room temperature and potassium-Iert-
butoxide (1.10 g, 9.69 mmol) was added to it. The resulting mixture was retluxed for 24
h, cooled and diluted with water (IOOml). The aqueous layer was separated and extracted
with ethyl acetate (20 ml X 2). The ethyl acetate extracts were combined with toluene
layer and were subjected to evaporation under reduced pressure. The resulting residue
containing compound lOa was purified using column chromatography (eluent: 0-50 %
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ethyl acetate in hexane); pale yellow liquid; I H NMR (500 MHz, Chlorofoml-d) /) 8.97
(d, J = 7.5 Hz, IH), 8.22 (d, J = I .4 Hz, I H), 7.95-7.86 (m, I H), 5.4 (q, J = 6.3 Hz, 2H),
4.86 (q, J = 5.9 Hz, 2H), 2.5 (s, 3H), 1.93 (t, J = 6.3 Hz, 3H), 1.22 (t, J = 5.9 Hz, 3H); 13C
NMR (175 MHz, Chlorofonn-d) /)178.9.176.9,165.8,143.7.137.7,130.4,126.5,121.9.
117.8,100.7,61.4,48.6,15.7,14.6,13.6; APCI-MS: 326.8 (Mc+I).
Ethyl I-Benzyl-7-chloro-2-(methylsulfonyl)-4-oxo-1 ,4-dihydroquinoline-3-
carboxylate (lOb)
It was prepared utilising the method for the preparation of lOa using benzyl
isothiocyanate (4.90 gm, 32.9 mmol); pale yellow liquid; I H NMR (500 MHz,
Chlorofoml-d) 0 7.99 (d. J= 7.5 Hz, IH), 7.62 (d, J= 1.4 Hz, IH), 7.36 (dd, J= 7.5,1.4
Hz, I H), 7.28 (s, 5H), 5.43 (s, 2H), 4.19 (q, J = 5.9 Hz, 2H), 2.43 (s, 3H), 1.26 (t, J = 5.9
Hz, 3H); 13C NMR (175 MHz, Chlorofonn-d) /)178.9.167.5,165.8,140.9,137.6,136.9,
130.4,128.5,128.4,128.0,126.5,120.6,118.3,100.3, 61.4, 54.7,15.7,14.6; APCI-MS:
388.0 (M'+I).
Ethyl 9-Ethyl-7-chloro-3-hydroxy-4-oxo-4,9-dihydrothienoI2,3-blquinoline-2-
carboxylate (12a)
Toa solution of lOa (1.30 g, 4.00 mmol) indichloromethane maintainedatO"C,
/11- chloroperoxybenzoic acid (1.18 g, 6.89 mmol) was added under stirring and the
stirring was continued at the same temperature for 4-5 h. The mixture was then wanned
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upto the room temperature and allowed to stir for another 10-12h. The reaction mixture
was then neutralised using 3% sodium bicarbonate solution (10 ml) and washed with a
brine solution. The organic layer was separated,dried over sodium sulfate and evaporated
under reduced pressure to afford compound Ila as a white amorphous powder. This
product was then subjected to further reaction without purification. In a round bottom
Onsk, a mixture of compound Ila, ethyl mercnptoacetate ( 0.3 g, 2.58 mmol),
triethylamine (1.2 ml, 8.0 mmol) in absolute ethanol (30ml) was reOuxed for 5 h under
argon atmosphere. The solvent was evnporated to dryness under reduced pressure, waler
(20m I) was then added and Ihe resulling solid was filleredout. Furlherpurilicalionwns
achievedbyrecrystallizalionfromethanollogivecompoundl2aasa highly viscous
yellow liquid; I H NMR (500 MHz, Chlorofoml-d) I) 7.95 (d, J = 7.3 Hz, I H), 7.37 - 7.32
(m, 2H), 5.02 (s, IH, OH), 4.37 (q, J = 5.9 Hz, 2H), 4.05 (q, J = 6.2 Hz, 2H), 1.34 (I, J =
5.9 Hz, 3H), 1.29 (t, J = 6.3 Hz, 3H); 13C NMR (175 MHz, Chloroform-d) I) 180.8, 180.0,
164.0, 162.0, 143.7, 137.7, 130.4, 126.5, 121.9, 117.8, 111.1, 109.4,61.4,48.6, 14.6,
13.6; APCI-MS: 352.1 (M1+I)
Ethyl 9-Benzyl-7-chloro-3-hydroxy-4-oxo-4,9-dihydrothienoI2,3-blquinoline-2-
carboxylate (12b)
II was prepared ulilising Ihemelhod forlhe preparalionofl2a using IOb(I.60g,
4.00 mmol); highly viscous yellow liquid; I H NMR (500 MHz, Chloroform-d) I) 7.84 (d,
.J = 7.5 Hz, IH), 7.53 (d, J = 1.6 Hz, IH), 7.35 (dd, J = 7.4, 1.5 Hz, IH), 7.33 - 7.27 (m,
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5H), 5.45 (s, 2H), 5.10 (s,IH, OH), 4.39 (g,J= 5.9 Hz, 2H), 1.34 (t,J= 5.9 Hz, 3H); IJC
NMR (175 MHz, Chloroform-d) &182.2, 181.2, 165.2, 153.4, 142.1, 138.8, 138.1, 131.6,
129.7,129.6,129.2,127.7,121.8,119.5, 111.5,110.6,62.6,55.9,15.8; APCI-MS: 414.\
(M'+I).
Ethyl 9-Ethyl-3-hydroxy-4-oxo-7-(piperazin-l-yl)-4,9-dihydrothieno12,3-bIqu inoline-
2-carboxylate (13a)
To a mixture of compound 12a (0.70 g, 2.00 mmol) in DMF (10 ml), 0.86 g (10
mmol) of piperazine was added and the mixture was stirred at 140°C for 15-18h.ltwas
then brought up to room temperature and the title compound was precipitated by the
addition of 100 ml saturated solution of sodium chloride. The precipitate was washed
with water and purified by recrystallisation from ethanol; pale yellow solid; mp > 250°C;
I H NMR (500 MHz, Chloroform-d) 0 7.78 (d, J = 7.5 Hz, I H), 6.67 (dd, J = 7.5, 1.5 Hz,
I H), 6.52 (d, J = 1.5 Hz, I H), 5.4 (s, I H, OH), 4.37 (g, J = 5.9 Hz, 2H), 4.02 (g, J = 6.3
Hz, 2H), 3.50 (t, J = 5.0 Hz, 2H), 3.30 (t, J = 4.9 Hz, 2H), 3.07 (t, J = 5.0 Hz, 2H), 2.93 (t,
J = 5.0 Hz, 2H), 1.34 (t, J = 5.9 Hz, 3H), 1.29 (t, J = 6.3 Hz, 3H), 1.21 (s, I H); IJC NMR
(175 MHz, Chlorofonn-d) 8 179.6, 172.5, 166.5. 156.6, 146.1, 132.5. 113.8, 108.8, 107.8.
106.1, 68.9, 63.4, 61.4, 50.1, 49.2, 45.0, 14.6, 14.3; HR-MS (TOFEI) calcd for
C2oH2JNJ04S (401.1410); found (401.1410).
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EthyI9-Ethyl-3-hydroxy-4-oxo-7-(4-methylpiperazin-l-yl)-4,9-dihydrothienoI2,3-
blquinoline-2-carboxylate (13b)
Prepared according to the procedure employed for the preparation of compound
13a, using (0.70 g, 2.00 mmol) of compound 12a and 1.00 g (10 mmol) of
methylpiperazine; yellow solid, mp 245-247 ilC; I H NMR (500 MHz, Chloroform-d) 0
7.79 (d, J = 7.4 Hz, I H), 6.67 (dd, J = 7.4, 1.5 Hz, I H), 6.63 (d, J = 1.6 Hz, I H), 4.8 (s,
I H,OH), 4.37 (q, J = 5.9 Hz, 2H), 4.03 (q, J = 6.3 Hz, 2H), 3.44 (t, J = 5.1 Hz, 4H), 2.35
(t, J = 5.1 Hz, 4H), 2.2\ (s, 3H), 1.34 (t, J = 5.9 Hz, 3H), 1.26 (t, J = 6.3 Hz, 3H); 1JC
NMR (175 MHz, Chloroform-d) 0 176.6,175.9. 162.4. 160.8. 153.4. 142.0. 132.6. 116.8.
116.7,115.8,110.2,103.0,61.4,52.5,50.1,48.6,46.0, 14.6, 13.4; HR-MS (TOFEI) calcd
forCclH25NJ04S (4/5.1564); found (4/5.1578)
Ethyl 9-Ethyl-3-hydroxy-4-oxo-7-(morpholin-4-yl)-4,9-dihydrothienoI2,3-
blquinoline-2-carboxylate (13c)
Prepared utilizing the procedure employed for the preparation of compound 13a,
using (0.70 g, 2.00 mmol) of compound l2a and 0.87 g (10 mmol) of morpho line; white
solid; 238-240 ilC; I H NMR (500 MHz, Chlorofon11-d) 0 7.97 (d, J = 7.5 Hz, I H), 6.88
(dd, J = 7.5, 1.4 Hz, I H), 6.80 (d, J = 1.6 Hz, I H),5.6 (s, I H, OH), 4.58 (q, J = 5.9 Hz,
2H), 4.24 (q, J = 6.3 Hz, 2H), 3.94 (t, J = 4.6 Hz, 4H),3.58 (t, J = 4.6 Hz, 4H), 1.55 (t, J =
5.9 Hz, 3H), 1.48 (t, J = 6.3 Hz, 3H); 1JC NMR (175 MHz, Chlorofon11-d) 0 182.0. 181.2.
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165.2,163.3,154.5,143.2,133.8,118.0,117.4,112.3,110.6,104.2,67.0,62.6,49.8,
48.4, 15.8, 14.8; HR-MS (TOFEI) calcd for C211H22N20SS (402.1249); found (402.1241).
Ethyl 9-Ethyl-3-hydroxy-4-oxo-7-(pyrrolidin-l-yl)-4,9-dihydrothieno12,3-
blquinoline-2-carboxylate (13d)
Prepared utilising the procedure employed for the preparation of compound 13a,
using (0.70 g, 2.00 mmol) of compound 12a and 0.71 g (10 mmol) ofpyrrolidine; white
amorphous solid; 241-243 IIC; I H NMR (500 MHz, Chlorolonn-d) 07.71 (d. J = 7.5 Hz,
I H), 6.67 (dd, J = 7.5, 1.4 Hz, IH), 6.39 (d, J = 1.4 Hz, 1H), 4.64 (s, I H, OH), 4.37 (g, J
= 5.9 Hz, 2H), 4.01 (g, J = 6.3 Hz, 2H), 3.41 (ddd, J = 6.5, 4.2, 2.6 Hz, 4H), 2.08 - 2.00
(m,4H), 1.34 (t, J = 5.9 Hz, 3H), 1.28 (t, J = 6.3 Hz, 3H); 13C NMR (175 MHz,
Chlorofolln-d) 0 176.1. 175.8,162.4.160.8,153.6,141.8.134.5,116.7.114.3,113.3,
110.2,100.8,61.4,51.2,48.6,26.0,14.6,13.7; HR-MS (TOFEI) calcd for C2oHnN204S
(386.1300); found (386.1319).
Ethyl 9-Benzyl-3-hydroxy-4-oxo-7-(piperazin-1-yl)-4,9-di hydrothieno12,3-
blquinoline-2-carboxylate (13e):
Prepared according to the procedure employed for the preparation of compound
13a, using (0.82 g, 2.00 mmol) of compound 12b and 0.86g (10 mmol) of piperazine; off-
white solid; mp > 250 IIC; I H NMR (500 MHz, Chlorofonn-d) 07.79 (d, J= 7.5 Hz, I H),
7.34 - 7.27 (m, 5H), 6.89 (d, J = 1.4 Hz, 1H), 6.67 (dd, J = 7.5, 1.4 Hz, 1H), 6.20 (s, I H,
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OH), 5.40 (s, 2H), 4.37 (g, J = 5.9 Hz, 2H), 3.57 (t, J = 5.0 Hz, 2H), 3.30 (t, J = 5.\ Hz,
2H), 3.15 (t, J = 5.1 Hz, 2H), 2.89 (t, J = 5.0 Hz, 2H), 1.36 (s, I H), 1.34 (t, J = 5.9 Hz,
3H); 13C NMR (175 MHz, Chlorofonn-d) 8 182.0. 181.2, 165.3, 154.1. 153.4. 141.9,
138.1,134.0,129.7,129.5, 129.3,118.2,116.0,111.5,110.6,104.6,62.6,55.9,51.3,
46.2, 15.8; HR-MS (TOFEI) calcd for C15H15NJ04S (463.1565); found (463.1563).
Ethyl 9-Bcnzyl-3-hydroxy-4-oxo-7-(4-mcthylpipcrazin-l-yl)-4,9-dihydrothicnoI2,3-
blquinolinc-2-carboxylatc (13t)
Prepared utilizing the procedure employed for the preparation of compoundl3a,
using (0.82 g, 2.00 mmol) of compound 12b and 1.00 g (10 mmol) of methylpiperazine;
brown solid; mp> 250°C; I H NMR (500 MHz, Chloroform-d) 8 7.75 (d. J = 7.5 Hz. I H).
7.34 - 7.25 (m, 5H), 6.69 - 6.63 (m, 2H), 5.45 (s, 2H), 5.01 (s, 1H,OH), 4.37 (g, J = 5.9
Hz, 2H), 3.44 (t, J = 5.2 Hz, 4H), 2.35 (t, J = 5.2 Hz, 4H), 2.26 - 2.18 (m, 3H), 1.34 (t, J =
5.9 Hz, 3H). IJC NMR (175 MHz, Chlorofonn-d) 8 181.3. 180.0. 170.9. 167.8, 160.1,
147.0,135.4,130.4,128.9,127.8,126.7,125.4,125.3,119.6,114.2,103.7,62.6,60.2,
46.0, 35.2, 15.1, 14.2; HR-MS (TOFEI) calcd lor C16H17NJ04S (477.1722); found
(477.1705).
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EthyI9-Benzyl-3-hydroxy-4-oxo-7-(morpholin-4-yl)-4,9-dihydrothienoI2,3-
blquinoline-2-carboxylate(13g)
Prepared utilizing the procedure employed tor the preparation of compound 13a,
using (0.82 g, 2.00 mmol) of compound 12b and 0.87 g (10 mmol) of morpho line; white
solid; 238-240 DC; I H NMR (500 MHz, ChlorofOlm-d) 8 7.77 (d, J = 7.5 Hz, IH), 7.26-
7.16 (m, 5H), 6.64 (d, J = 1.4 Hz, I H), 6.58 (dd, J = 7.5, 1.4 Hz, I H), 5.40 (s, 2H), 4.61
(s, IH, OH), 4.28 (q, J = 5.9 Hz, 2H), 3.64 (t, J = 4.5 Hz, 4H), 3.28 (t, J = 4.5 Hz, 4H),
1.25 (t,J= 5.9 Hz, 3H); 13C NMR (175 MHz,Chlorofonn-d) 8180.8. \80.0. 164.0. 152.9.
152.2,140.7,136.9,132.8,128.5,128.4,128.0,116.9, 114.8, 110.3, 109.4, 103.4,65.8,
61.4, 54.7, 47.2, 14.6; HR-MS (TOFEI) calcd for C 2,H24 N20,S (464.1405); found
(464.1436).
Ethyl 9-Benzyl-3-hydroxy-4-oxo-7-(pyrrolidin-l-yl)-4,9-dihydrothienoI2,3-
blquinoline-2-carboxylate (13h)
Prepared utilising the procedure employed for the preparation of compound 13a,
using(0.82g, 2.00 mmol) of compound I2b and 0.71 g(IO mmol)ofpyrrolidine; white
amorphous solid; 245-246 °C; I H NMR (500 MHz, Chlorofoml-d) 8 7.87 (d. J = 7.5 Hz,
IH), 7.37 (d,J= 1.4 Hz, IH), 7.33 -7.28 (m, 5H), 7.14 (dd,J= 7.5, \.4 Hz, IH), 5.52 (s,
2H), 4.78 (s,1 H,OH), 4.37 (q, J = 5.9 Hz, 2H), 2.07 - 1.98 (m, 2H), 1.73 - 1.61 (m,4H),
1.58 (dddd, J= 12.3,8.7,6.2,3.0 Hz, 2H), 1.34 (t, J= 5.9 Hz, 3H); I3C NMR (175 MHz,
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Chlorofoml-d) I) 180.8. 180.0, 164.0, 152.6, 152.2. 140.5. 136.9. 134.7. 128.5, 128.4,
128.0, 113.4, 112.8, 110.3, 109.4, 100.9,61.4,54.7,51.1,25.9, 14.6; HR-MS (TOFEI)
calcd for C25H24N204S (448.1456); found (448.1450)
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3.1 Conclusion and future research
Dl1Jgs that act against various strains of bacteria are known as antibacterial agents.
Quinolones have been used extensively as antibacterial agents . The very first members of
quinoloneantibacterial family were eventually phased out of therapeutic system, mainly
because of development of bacterial resistance and hightoxici ty.Successivegenerations
ofquinolonesincludeseveralbroadspectl1Jmandpotentantibacterials that are currently
in use including ciprofloxacin and ofloxacin. However, the emergence of bacterial
resistanceagainstquinoloneantibacterialsisthemajorchallengefortheresearchers.
Recent works on stl1Jcture activity relationships ofquinolones have revealed that non-
tluorinatedanaloguesaremoreactiveagainstantibioticresistantbacterialspecies[I-5].
Daneshtalab group has long been involved in quinolone-based research. Various novel
quinolone-basedcompoundshavealreadybeensynthesizedinourgroup. For this thesis, a
patent by Katsumi el 01. had drawn our attention [6]. As described in Chapter 2 of this
thesis, the above researchers focused on the synthesis and biological evaluation of
tricyclic quinolones and discovered that compound A,a polycyclic tluorinatedquinolone.
demonstrated good antibacterial activity. Ranjith Garlapati [7], a graduate student in
Daneshtalabgroup, has also attempted working on the synthesis andanticancerevaluation
ofa series of novel compounds that werestl1Jcturally related to compoundA. To expand
thestl1Jcture-bioactivityprofileofthesetricyclicquinolones,wepursued further study on
thestructuralmodificationsofcompoundA.lnthiscontext,weprepared a series of non-
tluorinated derivatives of polycyclic quinolones and tested them against different
bacterial strains. Unfortunately none of the synthesized compounds were active. To
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explore the possible cause lor the loss of antibacterial activity in this series of
compounds, we decided to do molecular docking on DNA gyrase enzyme, a bacterial
enzyme that is potentially inhibited by the quinolone class of compounds (please see the
details in Chapter 2 of this thesis).
The findings of docking studies were quiet interesting. Our synthesized compounds as
well as our standard (Compound A) were able to interact with the ATP binding domain of
DNA gyrase as well as the DNA-DNA gyrase complex. Based on docking energies, it
was found that, although the test compounds were interacting with the enzyme, they were
forming a reversible binding with the various domain of the gyrase enzyme, while
compound A and other active antibacterial quinolones form irreversible binding with the
ATP binding site of the gyrase molecule. The reversible interaction of the test compounds
with the ATP binding site of the gyrase may be the main reason for the low of activity of
these compounds, as discussed in chapter 2 of this thesis.
Fig3-1: Structure of Compound A
Quinolones have a very unique mechanism of action by which they not only inhibit the
bacterial growth, but also disrupt the activities of two very essential enzymes, DNA
gyrase and topoisomerase IV, resulting in generation of high levels of double-stranded
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D A breaks and bacterial death. Quinolones can selectively target either of these
enzymes in different bacteria. This unique feature ofquinolones can be viewed as a
potential aspect for qui no lone-based anticancer agents. There are two main slluctural
requirements for a quinolone to interact with D A topoisomerases. One of these features
is their ability to chelate the Mg~' at the active site and to complex with the ATP binding
region. In our research group, Dr. AbeerAhmedhassynlhesizedvariousquinolonebased
molecules, with potential anti-cancer activity. Compounds synthesized by her were able
to bind with the ATP binding region but were not able to make appropriate chelation with
the Mg '2 This was the cause behind the absence of cytotoxicity [8a-b].
As a part of my future research plan, I will try to work on further stnlctural optimisation
of my test compounds, to explore various other activities. One of them will include
development and synthesis of various carboxylic acid- orcarboxamide-based polycyclic
quinolones as depicted in Figure 3-2. These substituents will delinitely help to chelate the
Mg'}attheactivesiteoftopoisomerase,toa larger extent, as compared with the ester
mOiety.
Wlwrc.Rispipcrazinc/mclhylpipcrazil1l:/MmpholincClt:
:.Illd RI is COOl I / rON II~ elC
Figure 3-2: Proposed structure of various quinolone based derivatives
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